Iron prophylaxis in pregnancy Intravenous Versus Oral route by Dheepa Jayanthi, R
IRON PROPHYLAXIS IN PREGNANCY- 
 
INTRAVENOUS VERSUS ORAL ROUTE 
 
 
 
 
 
 
DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT 
FOR 
M.D DEGREE 
BRANCH - II 
OBSTETRICS & GYNECOLOGY, 
MADRAS MEDICAL COLLEGE, 
CHENNAI - 3. 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
 
CHENNAI - 1. 
 
APRIL  2013 
 
 
 
 
  
 
CERTIFICATE 
 
 
 
This is to certify that the dissertation entitled “IRON PROPHYLAXIS 
IN PREGNANCY – INTRAVENOUS VERSUS ORAL ROUTE” AT ISO-
KGH is a bonafide work done by Dr.R.DHEEBA JAYANTHI in the Institute 
of Social Obstetrics, Govt Kasturba Gandhi hospital(Madras Medical College)  
Triplicane , Chennai  in  partial  fulfillment  of  the  university rules  and 
regulations for award of MD degree in Obstetrics and  Gynecology under my 
guidance and supervision during the academic year 2010-2013. 
 
 
 
 
 
 
 
 
 
 
 
Prof. DR.V.KANAGASABAI M.D  Prof. DR.DILSHATH..  M.D., DGO. 
DEAN,  Director and Superintendent 
Madras Medical College,  Institute of Social Obstetrics, 
     Rajiv Gandhi Govt. general hospital  Govt Kasturba Gandhi hospital for                                                            
     Chennai-3                                                  women and children,  
                                                                        Madras medical college, 
                                                                              Chennai – 3 
 
 
 
 
 
 
 
 
 Prof. DR.P.M.GOPINATH, M.D., DGO. 
 Guide, 
 
Institute of Social Obstetrics, 
Madras medical college, Chennai- 3 
                                   DECLARATION 
 
 
 
 
 I. Dr.R.Dheeba jayanthi , solemnly declare that the dissertation 
titled “IRON PROPHYLAXIS IN PREGNANCY – INTRAVENOUS 
VERSUS ORAL ROUTE” was done by me at The Institute of social 
obstetrics, Govt Kasturba Gandhi Hospital, Madras Medical College during 
2010-2013 under the guidance and supervision of Prof. Dr.P.M.GOPINATH 
MD,DGO. This dissertation  is submitted to the Tamilnadu Dr. M.G.R. 
Medical University, Chennai in partial fulfillment of the rules and regulations 
for the M.D. Degree Examination in Obstetrics and Gynecology. This has not 
been submitted previously by me for the award of any degree or diploma from 
any other university. 
 
 
 
 
Place:Chennai-3 Signature of Candidate 
 
Date: Dr. R. DHEEBA JAYANTHI M.B.B.S 
MD PostGraduate Student 
Institute Of Social Obstetrics, 
Govt .Kasturba Gandhi Hospital 
Chennai. 
 
 
 
 
 
 
Prof. DR.P.M.GOPINATH.M.D., DGO. 
Guide, 
Institute Of Social Obstetrics, 
Govt. Kasturba Gandhi Hospital 
Chennai. 
 
 4 
 
                        ACKNOWLEDGEMENT 
  
I extend my gratitude to the Dean Prof Dr. V. KANAGASABAI M.D. 
Madras Medical College, Chennai, for his kind permission to do this 
dissertation and to use the hospital resources for this study. 
 I am extremely thankful and grateful to my respected Director Prof Dr. S. 
DILSHATH  M.D., D.G.O. Institute of Social Obstetrics and Government 
Kasturba Gandhi Hospital, Chennai for providing with the necessary 
facilities to carry out this study and her continuous support and guidance. 
I am grateful and greatly indebted to Prof . Dr. P.M. GOPINATH M.D., 
D.G.O. Institute of Social obstetrics  and Government Kasturba Gandhi 
Hospital, Chennai for his able guidance. 
I extend my profound gratitude to all unit Chiefs, Registrar, Assistant 
Professors for their boundless affection and support for my study. 
I am ever grateful for all the pregnant women who participated in this study 
without  whom this study would not have been possible. 
I thank Mr. PADMANABAN, statistician, who helped me for statistical 
analysis. 
I thank my family & friends for their inspiration & support given to me. 
 
 
 5 
 6 
 
 
 
 
 
 7 
 
                                    INDEX 
 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S NO CONTENTS PAGE NO 
1 Introduction 1 
2 Aim of  the study 8 
3 Review of literature 9 
4 Overview 22 
5 Materials and Methods 50 
6 Results and Analysis 54 
7 Discussion 70 
8 Summary 77 
9 Conclusion 79 
10 Appendices  
 i. Bibliography 80 
 ii. Proforma  
 iii. Abbrevation  
 iv. Master Chart  
 v. Key to Master Chart  
 8 
 
 
 
  
 
 
 
 
 
 
                  
                                 
INTRODUCTION 
 9 
INTRODUCTION 
 
Child birth should be a joyous event. Pregnancy is a physiological 
Phenomenon. The physiological effects of pregnancy should be taken care at 
the earliest and we should not let one die of physiological phenomenon. 
  Iron is very important for the normal function and development of the 
organs in the fetus. In order to prevent iron deficiency in the fetus, we have  
 to ensure an adequate iron status in pregnancy. 
Maternal mortality is around 350- 450/100000 live births in India. 
Anaemia contributes 20% of maternal deaths. Risk of perinatal mortality is 
nine times higher. Bayley mental development index shows poor 
performance in children born to mothers affected by iron deficiency anemia. 
Most common nutritional disorder affecting majority of population in 
the world is Iron deficiency.  About 25% of world population  is affected by 
iron deficiency.  Pregnant women are at high risk of iron deficiency anemia, 
because of increased iron needs during pregnancy. 
Iron deficiency anemia in mother during pregnancy leads to Iron 
deficiency anemia in infancy and childhood. At two months of age and 
beyond the iron reserves in infants doubles in women taking iron when 
compared to unsupplemented mothers. The definite solution for this is to 
eradicate iron deficiency during pregnancy. 
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There is a wide geographical variation in the incidence of iron 
deficiency and iron deficiency anemia in pregnancy . Because of high levels 
of  anemia in pregnancy, National Nutritional Anaemia control programme 
was started in 1970. This is now called as Iron and Folic acid program. 
According to NNACP “iron and folic acid tablets must be  given to all 
antenatal mothers from second trimester to three months of  lactation”.  
  This Program has been taken up by the maternal and child health 
division of health and family welfare. It is now part of Reproductive and 
child health program. In this Pregnant women were recommended to have   
one tablet per day containing 100 mg of  elemental iron and 500 μg folic 
acid for 100 days from second trimester of  pregnancy  till 3 months of  
lactation.  Preschool children (aged 1–5 years) were recommended to take 
one  tablet (pediatric tablet contains 20 mg iron and 100 μg folic acid) per 
day for 100 days every year.(5) 
The rationale  behind the IFA program was to decrease the incidence 
and Prevalence of anemia in the reproductive age group women (4). 
Number of studies, surveys or audits was conducted to assess the 
prevalence of anemia in women in India, so as to assess the impact of IFA 
Program. The prevalence according to various studies is as follows. 
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According to NFHS I (1995) only 40% of rural women receive care 
from a physician during at least one antenatal visit and out of them Only 
45% receive Iron – Folic acid tablets. (1) 
According to NFHS- II (2002) In pregnant women the prevalence of 
anemia was 49.7% . In breast feeding women the prevalence is around 
56.4%.Among non pregnant and non breast feeding women the prevalence is  
around 50.4%.(2) 
NFHS – III (2008) was carried out in 2005-2006. According to NFHS 
–III  prevalence of anaemia is 57.9 % in  pregnant women, 54.6% in urban 
and 59%  in rural.(3) 
District Level Household Survey (DLHS 2, 2006) is one of the largest 
health surveys conducted, involving 700,000 households covering 563 
districts of  the country. According to this study70% of pregnant women and 
adolescent girls in the country were anemic.  
After 30 years of starting IFA Program, still the prevalence of iron 
 
 deficiency anemia in pregnancy is on the rising trend. The prevalence is in  
 
the range of 50- 60%. 
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The reasons for failure of IFA program are 
 
 Partial coverage of population 
 
 Defective absorption due to intestinal infestation 
 
 Improper consumption 
 
 Diet with high iron chelators 
 
 Failure to replenish stores 
 
 Because of lack of health education and supervision 
 
 Failure with delivery system 
 
 Failure to deworm prior to iron supplementation 
 
 
The solution for the failure of delivery system is to include NGO, 
school system, women’s club with community leaders who could distribute 
the tablets so that the iron tablets would reach the women at their door steps.  
There is evidence to say that, even when the women receive the 
tablets, actual consumption is not ensured. 
NFHS – II (1998-1999) conducted a study for urban slum dwellers in 
Madhya Pradesh. According to the study, only 61.1% of pregnant women 
consumed the required number of tablets (6) 
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According to RCH report from Government of India, even in areas of 
high coverage of 86.2%, only 11.5% of them actually consumed them for 
more than 3 months during their pregnancy. 
According to Nutrition Foundation India Survey (2003)  pregnant 
women who received IFA tablets were only 32% and out of them only 4.9% 
consumed it. 
Indian Council of Medical Research conducted a study on why 
women would accept IFA tablets but failed to consume the required numbers 
(ICMR 1985, 1989) 7, 8 
 
The reasons are as follows: 
 
 Some women did not like the taste of the tablet. 
 
 Some women found the tablets foul smelling. 
 
 Some forgot to consume the tablet due to household workload. 
 
 Some women believe that consumption of iron tablets results in big 
baby resulting in difficulty in delivery. 
 
The side effects of oral iron supplements increases with higher 
dosages and leads to poor compliance. We can minimize this by prescribing 
single tablet at bedtime or by biweekly regimen. 
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According to World Health Organization (WHO), oral iron program 
have often failed to reduce frequency of iron-deficiency anemia. High levels 
of iron-deficiency anemia exist in pregnancy despite routine use of iron 
prophylaxis adopted by many centres in the developing world. 
       The WHO technical working group on the prevention and the 
treatment of severe anemia has stated that parenteral iron therapy produces a 
rapid and complete correction of iron deficiency, including replacement of 
iron stores producing a more rapid erythropoietic response than oral iron 
replacement. 
Fresh thinking is therefore necessary to overcome the reasons for 
failure of  IFA program. It has been widely studied that intravenous iron 
Supplementation is very effective in the treatment of iron deficiency anemia  
in pregnancy. There is strong evidence to show that intravenous iron sucrose 
show a rapid improvement in iron deficiency anemia when compared to oral 
iron.  
As iron sucrose is given intravenously, it overcome the problem of  poor 
compliance which is one of the most common reason for failure of IFA 
program. The side effects are minimal with iron sucrose, anaphylactic  
reactions are rare  with iron sucrose when compared with  intravenous iron 
dextran. Iron sucrose can be given to all pregnant women irrespective of iron  
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status at the time of booking and at the time of antenatal visit under the 
supervision. So all the women restore body iron stores more rapidly, and a 
prompt increase in hemoglobin is more likely to be achieved.  
 
We conducted a study to assess the efficacy and safety of intravenous 
 
 iron sucrose versus oral ferrous sulphate in the prophylaxis of gestational  
 
anemia 
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AIM OF THE STUDY: 
A. To assess the response of intravenous iron sucrose with that of oral 
ferrous   sulphate in the prophylaxis of Iron deficiency anemia in 
pregnancy.  
 
B. To compare the efficacy and safety of two and three doses of 
intravenous iron sucrose with daily oral ferrous sulphate in the 
prophylaxis of gestational anemia in pregnant women.  
 
 
C. To compare the acceptability, efficacy and side effects of injectable 
iron sucrose over oral ferrous sulfate in the prophylaxis of anemia in 
pregnancy. 
 
PRIMARY OBJECTIVE: 
Whether Iron sucrose can be used as an alternative in the prophylaxis 
of iron deficiency anemia in pregnancy, so that maternal morbidity and 
Mortality due to anemia can be reduced. 
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REVIEW OF LITERATURE 
 
 
1. International journal of gynaec and obstetrics (2005) 90,238- 239. A.Dede 
etal  D.Uygus, B.Yilmaz T.mungan, M.Ugur They have done a comparative 
study in the treatment of iron deficiency in postnatal women. 75 women 
whose Hemoglobin <=9g/dl were included in the study. They were allotted 
into one of two groups , 50 patients in intravenous group and 25 patients in  
oral group. Patients in intravenous group were given calculated dose of iron  
sucrose and patients in oral group received 300mg tablets of ferrous sulphate 
thrice daily one hour before meals. Blood was  taken before starting 
treatment and at days 7 and 28.The  following parameters were assessed 
Hb%, Hematocrit, C Reactive protein, serum ferritin, serum iron mean 
corpuscular volume (MCV) and  serum iron  binding capacity. They 
concluded that intravenous iron therapy with iron  sucrose significantly 
raised  the serum ferritin level within a short period of  time with minimal  
side effects than oral iron therapy in   postpartum iron deficiency 
anemia(53). 
 
 
2. British journal of Obstetrics and Gynaecology, Sep 2006; 1248-1252. 
Bhandal.N et al .Russell. R This was a prospective randomized study in the 
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treatment of iron deficiency anemia in postnatal mothers. After  24-48 hours 
of delivery Hb was done and 44 women with Hb< 9 g/dl were included in 
the study. 22 women in group A were given 200 mg of iron sucrose on days 
2 and 4. 22 women in oral group were given 200 mg tablet of ferrous 
sulphate twice a day for 6 weeks.  
They found an average rise in Hb of  2.5gm/dl on day 5 in  
intravenous group and in the oral group average rise was 0.7gm/dl . There 
were no serious adverse effects in intravenous group .One third of  women 
in oral group had gastrointestinal side effects. 
They concluded that in women with postpartum iron deficiency  
anemia,  higher level of  blood Hemoglobin  was achieved in iron sucrose 
group when compared to oral group(52). 
 
 3. C Giannoulis et al A Danniilides, T Tantanasis, K Dinas, and J Tzafettas. 
Hippokratia, 2009 Jan – Mar: 13(1): 38 – 40. The efficacy of intravenous 
versus oral iron  was compared in 104 anaemic postpartum women. Women 
with hemoglobin of  <8 g/dl and ferritin < 10μg/dl were included in the 
study.  
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They concluded that in intravenous group the mean rise in  Hb  level 
was 4.6g/dl and of mean rise in  ferritin  level was 105 mg/l. In oral group 
the mean rise in  Hb level was2.3 g/dl and the rise in  ferritin level was  
68mg/dl.  
 
They observed a Significant difference between the two groups, in the 
rise of hemoglobin level (p=0.0001) and also in the rise of ferritin level 
(p=0.000). The efficacy of intravenous iron sucrose was proved in the 
treatment of  iron deficiency anemia in the postpartum period(54). 
 
4. Khurshid shabbir Raja et al , (Rawal Medical Journal 2003;28:40-43). 
This study was carried out in anemic pregnant women to study the efficacy 
of intravenous iron sucrose. Fifty antenatal women with hemoglobin  8gm/dl 
were included in the study. Calculated dose of iron sucrose was given 
intravenously over several  sessions.  Hemoglobin (Hb) levels, serum 
ferritin, and mean corpuscular  volume measured. They noted significant rise 
in Mean Hemoglobin of 3.5 g/dl. Significant rise in Serum ferritin and MCV 
were noted. Iron sucrose complex , significantly improved the hematological 
parameters(55). 
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5.  Al-Momen Ak et al, al-Mechari A; al-Nuaime L  in 1996 conducted a  
study comparing Intravenous iron sucrose and oral ferrous sulphate.  
Significantly higher Hb level (p<=0.001) were observed in iron sucrose 
group when compared to oral group.No major side effects were noted in the 
Iron sucrose group. In the oral group there was about 30% of poor 
compliance(50).  
 
6. Scott B et al. silverstein and George M  Rodgers According to them , the 
increased availability of parentral iron preparation should decrease the need 
to use red cell transfusion in patients with iron deficiency anemia. They 
observed that increase in Hb is observed  after one week of iron sucrose 
administration and serious anaphylactic hypersensitivity of 0.002% in 
intravenous iron sucrose group compared to 0.6-0.7% in intramuscular  iron 
dextran group. 
 
7. Gravier A et al , Descargues G, Marpeace L et al (1999) conducted a  
study on how to avoid postpartum blood transfusions in Iron deficiency  
anemia patients, by  treating with I.V Iron sucrose. They concluded that I.V 
Iron sucrose is effective in preventing unnecessary blood transfusions in 
postpartum   patients(57) 
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8. Al Momen et al conducted a prospective study in 111 pregnant women 
with iron deficiency anaemia.  Women with Hb <9gm/dl were included in  
the study and divided into 2 groups. Intravenous iron sucrose was  given as  
an infusion in study group. 100mg of iron sucrose in 100ml of normal saline 
was given every 1 to 3 days. Controls were given  100mg of Iron  dextran 
on alternate days till the calculated dose was given. 
Intravenous iron sucrose group achieved a  higher levels of Hb, with 
in short period of time when compared with controls. Adverse effects were 
less with iron sucrose when compared to iron dextran group. 32% of  patient 
in iron dextran group were non compliant. 
9. Catherine Gay et al (2005) concluded that although oral iron is the 
standard   treatment for iron deficiency anemia, it is poorly tolerated and has 
low efficacy in rapid correction of anemia; But I.V iron sucrose is both 
quick and effective in treating anemia. The average mean rise of Hb was 0.8 
gm/dl for oral iron, 3.5 gm/dl for blood transfusion and 3.1gm/dl for I.V iron 
after 14 days. No serious adverse effects were noted for I.V iron sucrose. 
10. Bayoumeu Fet al, Subiran – Buisset E, Baka NE et al (2002) American 
Journal of obst. and Gynaecology also observed the effectiveness, safety and 
tolerability of I.V iron sucrose compared to oral iron for treatment of iron 
deficiency anemia in pregnant women. 
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11. Chamate E et al . conducted a study on treatment of iron deficiency 
anemia in pregnancy and immediate puerperium comparing I.V iron sucrose 
and oral ferrous sulphate and concluded that I.V iron sucrose is safe, 
convenient and more effective with less adverse effects and it can replace 
blood transfusion in antenatal period. 
 
12. Gabriela Bancaiova et al  Ursula Von Mandach, Roland Zimmerman- 
European journal of obstet and gynecology and reproductive biology, vol 
144 issue2 – June 2009; 135-139- done a comparative study between iron 
sucrose and oral iron  in the prophylaxis of gestational anemia in pregnant  
Women. Group A women were given two dose of 200mg iron sucrose 
Intravenously 4 weeks apart after 20 weeks . Group B women were given 
three doses of 200 mg of iron sucrose per dose intravenously 4 weeks apart. 
Group C women were given 100 tablets of ferrous sulphate for 100 days.  
There was no clinically significant difference in the hematological 
parameters in the iron sucrose group when given as  prophylaxis in pregnant 
women. 
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13. Kochhar et al , P. K., Kaundal, A. and Ghosh, P. (2012), Intravenous 
iron sucrose versus oral iron in treatment of iron deficiency anemia in 
pregnancy: A randomized clinical trial. Journal of Obstetrics and 
Gynecology Research. doi: 10.1111/j.1447-0756.2012.01982.x   This was a 
prospective study, where 100  antenatal women with hemoglobin 7–9 g/dL, 
MCV <85 fL and S. ferritin <15 ng/mL, were randomized into one of the 
two groups.  For women belonging to Group A 200 mg tablets of ferrous 
sulphate were given three times daily for 4 weeks. 200 mg of iron sucrose 
was given on  alternate days by slow intravenous infusion to the women 
belonging to group B. The parameters assessed were hemoglobin, 
reticulocyte count, red blood cell indices on days 7, 14, 21, and 30 and at 
delivery, and ferritin was measured  on day 30 and at delivery. Side-effects 
of treatment and the neonatal outcome were studied as secondary outcome 
measures. 
Results:  Statistically significant difference in rise of  hemoglobin levels 
(3.1 g/dL in group A vs 5.1 g/dL in group B; P = 0.002) and ferritin levels 
were noted  between the two groups on day 30 (P = 0.005).  
The adverse effects were more in oral group when compared to intravenous 
iron sucrose group. Neonatal outcome was comparable in the two groups. 
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14.  Gowda et al (2010) conducted a randomized prospective study to 
evaluate the safety and efficacy of intravenous iron sucrose. Antenatal 
women whose Hb less than 8 g/dl were included in the study. Hematological 
parameters were done on day 1,7,28. Calculated dose of iron sucrose 
200mg/dose was given on alternate days. Iron sucrose was found to be safe 
and effective in the treatment of  iron deficiency anemia in pregnancy. This 
study was sponsored by NRHM, Govt. of Karnataka, to study the efficacy 
and safety in pregnancy as a pilot project. After conclusion of this study, the 
Government made iron sucrose injection for use at Government  hospitals. 
This will benefit the society at large. 
 15.  Surriaya Halimi et al, Syed Muhammad Ashhad Halimi, Muhammad 
Shoaib conducted a comparative study  to evaluate the efficacy of oral  
versus  parenteral iron therapy for correction of anemia in pregnant women. 
100 pregnant women with Hb less than 11gm/dl and heamatocrit less than 
33% were selected and divided into two groups. Group-I  for oral and  
Group-II for intravenous administration of iron. The treatment results were 
assessed on day 30 of the treatment. 
Results: There was a significant rise in Hemoglobin in intravenous group on 
day 30 when compared to oral group. 
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They concluded that Parenteral iron therapy in form of iron sucrose is 
better choice to correct iron deficiency anaemia related to pregnancy. 
16.  Intravenous Iron Therapy for IDA in Pregnancy: (Divakar, Manyonda, 
et al. 2009)  They conducted a preliminary study of the efficacy, safety, and 
feasibility of the use of IV iron sucrose in iron deficiency anemia of 
pregnancy. 96 women who were anemic were enrolled in the study. These 
women had been given IFA tablets from the time of booking and for a 
minimum period of 4 weeks. when their Hb had remained below 11 g/dL 
after 4 weeks of therapy they are  declared as ‘’ failed to oral therapy”. 
Among them, those who were willing to receive IV iron sucrose were 
included in the study. The mean gestational age was 23.5 weeks (range 20–
34 weeks gestation) and the mean Hb was 9.2 g/dL (range 6.8–10.8 gm/dL). 
All the participants were dewormed with two tablets of Mebex Plus, prior to 
intravenous iron therapy. These women received two doses of IV iron 
sucrose of 200 mg per sitting, 3–5 days apart, on an outpatient basis and 
their Hb was estimated before and 4 weeks after therapy.  
The iron was administered either as a bolus push over 5 minutes or as 
an infusion over 30 minutes after dilution with 100 ml isotonic saline 
solution. Test dose was not given, and the patient was monitored for any 
adverse reactions over an hour following the first injection. The iron sucrose 
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was not calculated and given. They studied the response to a uniform dose of 
IV iron sucrose over a range of pretreatment Hb and found an optimal and 
quick response in all the patients 
A Cochrane review conducted in Pakistan reported that compared to 
intermittent iron supplementation , daily iron supplementation increases the 
haemoglobin level at the time of delivery among pregnant women in 
developing countries . 
According to a recently published randomized study there was  no 
difference in  pregnancy outcomes between daily and twice weekly iron 
supplementation. But the daily regimen improves the hemoglobin at term 
when compared to twice weekly regimen. 
The timing and dosage of oral iron are also controversial as most 
studies have focused on preventive treatment from midpregnancy, at or 
before 20 weeks gestation. 
Some researchers believe that both daily and weekly iron 
supplementation does not reduce the prevalence of anemia in pregnancy.  
We have to pay attention before the women become pregnant in the 
adolescent girls and women of reproductive age and provide them with 
sufficient and necessary micronutrients and low dose iron supplements. 
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Experiences on parenteral iron use are from the developed world. The study 
on prophylactic use of parenteral iron  in pregnancy is scanty , could be 
because of concerns about its adverse effects.  
The WHO technical working group has documented the efficacy in the 
prevention and treatment of severe anemia .  Parenteral iron therapy  when 
compared to oral therapy produces 
  rapid and complete correction of iron deficiency 
 Rapid replacement of iron stores 
 Rapid erythropoietic response . 
The indications for parenteral iron therapy are 
 Those who are unable to tolerate oral iron 
 Those in whom oral iron therapy fails due to noncompliance. 
 In Pregnancy For rapid restoration of hemoglobin in patients with 
severe anemia coming near term. 
 
Based on ferritin levels in early pregnancy we can go for selective 
administration in patients with low iron stores.  
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WHO recommends iron supplementation in accordance to prevalence. 
“In areas with prevalence of less than 40% , we have to supplement with 60 
mg of elemental iron daily for 6 months in pregnany. In  areas with 
prevalence of more than 40% continue supplementation for 3  months 
postpartum”. 
 
CDC recommends 30 mg of elemental iron supplementation.  
Food and Agriculture Organization of the United Nations concludes: 
“Iron requirements in the second and third trimesters cannot be satisfied by 
dietary iron alone, even if it is of high bioavailability and, unless stores of 
about 500 mg are believed to exist before pregnancy, administration of iron 
supplements may be indicated if impairment of the expected increase in 
hemoglobin mass in the mother is to be avoided” (58). 
Department of Health in United Kingdom states: “Ideally all women 
of childbearing age should have sufficient stores to cope with the metabolic 
demands made by pregnancy which can be met without further increase 
because of cessation of menstrual losses and by mobilisation of maternal 
iron stores and increased intestinal absorption. However, when iron stores 
are inappropriately low at the start of pregnancy, supplementation with iron 
may be necessary” (59). 
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The European Union states: “The physiologic solution for covering 
the high iron requirements in pregnancy is to use iron from stores. The 
problem, however, is that very few women, if any, have iron stores of this 
magnitude. Therefore, daily iron supplements are recommended in 
the latter half of pregnancy” (60). 
The Nordic Nutrition Recommendations states: “An adequate iron 
balance during pregnancy implies iron reserves of at least 500 mg. The 
physiologic iron requirements in the second half of gestation cannot be 
fulfilled solely through dietary iron” (61) 
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                                OVERVIEW     
 
  Anemia is said to be present when the hemoglobin (Hb) falls below a 
defined level or range. Due to physiological changes in the Hb concentration 
during the course of a normal pregnancy in a nonanaemic Women ,there is 
no universally accepted definition of anemia in pregnancy.  
 
WHO (1972):  WHO defines “Anemia as the presence of a Hb level of less 
than 11 g/dL during pregnancy and less than 10 g/dL in the puerperium”(14) 
 
US CDC (1989): CDC defines “Anemia as the presence of a hemoglobin 
level of less than 11 g/dL during the first and third trimesters (weeks 1–12, 
and 29–40 of pregnancy) and less than 10.5 g/dL during the second trimester 
(weeks 13–28 of pregnancy)”(15) 
 
ICMR (1989): According to ICMR “Anemia is defined by an Hb of less 
than 11.0 g/dL” and the severity of the anemia categorized as follows 
<4 g/dL = very severe 
4–6.9 g/dL = severe 
7–9.9 g/dL = moderate 
10–10.9 g/dL = mild” (16) 
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Types of Anemia Based on Cause: 
Anemia is most commonly caused by  
1) Iron deficiency 
2)  vitamins B12 and folic acid deficiency. 
3)  Chronic renal disease, chronic infestations and chronic 
inflammatory conditions may also be associated with 
anemia. 
Iron Deficiency and Iron-Deficiency Anemia: 
There is a state of iron deficiency that precedes iron-deficiency anemia. 
Various iron deficiency states are as follows:  
Absolute iron deficiency: 
Serum ferritin will be less than 15 μg/L, regardless of whether anemia is 
present.  
 Iron deficiency anemia: 
Serum ferritin will be less than 15 μg/L and Hb level fulfils the criteria 
of anemia.  
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Latent iron deficiency: 
Serum ferritin will be less than 15 μg/L, but Hb levels are within the 
non-anemic range. 
Functional iron deficiency: 
Serum ferritin is normal or even elevated, but transferrin saturation is 
decreased or the hypochromic erythrocyte fraction is greater than 10%.                   
STAGES OF IRON DEFICIENCY ANAEMIA: 
Stage I: Negative iron balance 
 Demands for iron exceed the iron absorbed  from  diet. 
 Depletion of storage iron. 
 Transport and functional iron is normal. 
 Normal Hb / hematocrit level with Normal RBC indices. 
 Serum Ferritin < 20ng/ml. 
Stage II: Iron deficient Erythropoiesis 
 Stored Iron become depleted. 
 Transport iron is reduced . 
 Serum iron begins to fall and total iron binding capacity rises 
gradually.  
 When the transferrin falls to 15 to 20%, Hb synthesis becomes 
impaired. 
 Increased erythrocyte protoporphyrin 
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Stage III: Iron deficiency anaemia: 
 Peripheral smear reveals microcytic and hypochromic picture 
appearing as  vacuolated red blood cells with reticulocytes in 
circulation. 
 Gradually Hb and hematocrit begins to fall.   
 Transferrin saturation < 15% 
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HAEMATOLOGICAL CHANGES IN STAGES OF IRON DEFICIENCY 
 
 NORMAL NEGATIVE 
IRON 
BALANCE 
IRON 
DEFICIENT 
ERYTHROPOIE
SIS 
IRON 
DEFICIENCY 
ANEMIA 
Marrow iron stores 1-3+ 0-1+ 0 0 
S. 
Ferritin(microgram/dl) 
50-200 <20 <15 <15 
TIBC(microgram/dl) 300-360 >360 >380 >400 
SI mg/dl 50-150 NL <50 <30 
Saturation % 30-50 NL <20 <10 
Marrow sideroblasts% 40-60 NL <10 <10 
RBC protoporphyrin 
(microgram/dl) 
30-50 NL >100 >200 
RBC morphology NL NL NL Microcytic 
Hypochromic 
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IRON METABOLISM IN PREGNANCY 
 Total body iron content of a pregnant woman is around 4 gms. 
 Out of this 
                        Haemoglobin                             –  70%,  
                        Hemosiderin and ferritin            -  25% 
                        Myoglobin                                  -  4.9% 
Majority of iron within the body exist in the form of haem 
Proteins(25). Like Hemoglobin , Myoglobin is oxygen carrying component 
in skeletal muscle. Deficiency of iron also affects myoglobin which is one of 
the causes for atonic PPH in anemic pregnant women.  
             Enzymes involved in bactericidal action require iron containing 
enzymes.  For optimum bactericidal action Myeloperoxidase in neutrophils 
requires iron. So, pregnant women who are anemic are thus prone for 
concurrent infections. 
           Iron is an important component of several respiratory proteins and 
enzymes and it serves as a carrier of oxygen. 
           One of the important enzymes involved in DNA synthesis is 
Ribonucleotide reductase , which requires iron for its optimum action. This 
is the reason for fetal growth restriction in pregnant women with iron 
deficiency anaemia. 
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In summary, the important bio-chemical functions of iron are  
               1. Cell division and differentiation, 
               2. Oxygen transport, 
               3. Electron transport and many other functions. 
               4. Catalyst for oxygenation and hydroxylation 
                5. Erythropoeisis 
 
DAILY REQUIREMENT: 
 
Adult male        - 0.5- 1 mg 
 
Adult female     - 1-2 mg 
 
Infants               - 60 microgram/Kg 
 
Children            - 25microgram/Kg 
 
Pregnancy         - 3 to 5 mg 
 
DIETARY SOURCES OF IRON: 
 
RICH SOURCES: 
 
                Liver, egg yolk, oyster, dry beans, dry fruits, wheat germ, yeast 
 
MEDIUM SOURCES: 
 
               Meat, chicken, fish, banana , spinach , apple 
 
POOR SOURCES: 
 
              Milk and its products, root vegetables 
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IRON REQUIREMENTS DURING PREGNANCY:  
The Iron requirement in pregnancy varies markedly in each trimester. 
Iron requirement decreases during first trimester due to stoppage of 
menstruation and account for saving of 0.56mg of iron/day. Iron 
requirements begin to increase in second trimester and it is on increasing 
trend throughout remainder of pregnancy. 
 
     As the pregnancy progresses, the requirements of iron for the fetus 
steadily increases in proportion to the weight of the fetus. The iron content 
of 3 Kg fetus is approximately <270 mg 
                    
An iron loss that occurs during parturition must also be added which 
includes 150 mg iron at blood loss and 90 mg in placenta and umbilical cord. 
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According to Council on Food and Nutrition, the requirements have 
been quantified as follows: 
               External iron losses                 - 170 mg 
              Expansion of red cell mass       -450 mg 
             Fetal iron                                   - 270 mg 
             Placenta and cord                      - 90 mg 
                          TOTAL                       - 980 mg 
 
 
   
IRON BALANCE IN PREGNANCY: 
Iron requirements rise to 4 mg in the second trimester and 6 mg in 
third trimester. Even from most optimal diet, iron requirements cannot be 
met with from dietary absorption.  
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Iron absorption is usually 3-4 mg/day, if the diet contains large 
quantities  of  bioavailable iron . But in developing country like us where the 
staple food is cereal amount of iron absorbed is lower. (26) 
 
 FACTORS FACILITATING IRON ABSORPTION: 
 
The heme form of iron has better bioavailability and is absorbed in 
ferrous form.  
 
 Ascorbic acid 
 
 Fermented food items 
 
 Gastric acidity 
 
 Low iron stores 
 
 Increased erythropoietic activity 
 
FACTORS INHIBITING IRON ABSORPTION: 
 
 Alkalis like Antacids 
 
 Phosphates 
 
 Phytates 
 
 Tannin 
 
 Tetracylines 
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TRANSPORT AND UTILIZATION: 
Free iron is highly toxic. Free iron on entering the plasma is 
immediately converted to ferric iron and is complexed with transferrin. The 
total plasma iron content is about 3 mg and is recycled about 10 times 
everyday. so the turnover of iron per day is around 30 mg/day. 
  Iron is transported into erythropoietic and other cells through specific 
membrane bound transferrin receptors. The complex is engulfed by the 
process of endocytosis. In the acidic PH of intracellular vesicles, Iron 
dissociates from the complex. The iron thus released is utilized for 
hemoglobin synthesis, while the transferrin and transferrin receptors return 
to the cell surface to carry fresh iron loads. 
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STORAGE AND EXCRETION: 
Iron is stored in reticuloendothelial cells in liver, spleen ,bone 
marrow, and also in hepatocytes and myocytes as ferritin and haemosiderin. 
Plasma iron derived from destruction of old RBCs , from stores and from 
intestinal absorption forms a pool that is available for erythropoiesis.  
  Iron is excreted mainly as exfoliated gastrointestinal mucosal cells, 
some RBCs, and in bile. Other routes are desqumated skin, very little in 
urine and sweat.  
The upper limit for iron tolerance in pregnancy is 45mg/day of iron. 
The adverse effects are less likely at this level.(IOM 2001) 
 
 CLINICAL FEATURES: 
 
1.  Mild anaemia may not have any effect on pregnancy. 
2.  Moderate anaemia may cause increased weakness, fatigue, lack of 
energy, and poor work performance. 
3.  Severely anemic woman may have palpitations,tachycardia, 
breathlessness, increased cardiac output leading on to cardiac stress 
which can cause decompensation and cardiac failure which may be 
fatal. 
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SIGNS: 
 
There may be no signs in mild anaemia. There may be pallor, glossitis 
and stomatitis. Patient may have edema due to hypoprotinemia. Soft systolic 
murmur can be heard in the mitral area due to hyperdynamic circulation. 
There can be fine crepitation at the base of lungs due to congestion. 
 
DIAGNOSIS: 
 
Hemoglobin: 
 
Haemoglobin estimation is the most practical method of diagnosis of 
 
 anemia. Though various methods like Taliquists method, copper sulphate 
 
 method and sahli’s method are  available. Cyanmethhaemoglobin method 
 
 appears to be the most accurate. 
 
Peripheral smear: 
 
Peripheral blood smear is another bedside indicator of diagnosis of 
anemia which will also differentiate between iron deficiency anemia, 
megaloblastic anemia and hemolytic anemia. 
RBC Indices: 
 
Mean corpuscular volume, Mean corpuscular hemoglobin and mean  
corpuscular hemoglobin concentration are all low in the iron deficiency 
anemia.  
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Serum Ferritin: 
 
 Serum Ferritin estimation refects iron stores 
 
 Ferritin is a  high molecular weight glycoprotein  
 Normal level of S. Ferritin is 15-300 microgram/dl 
 Level <12 microgram/dl indicates iron deficiency 
  It is stable, unaffected by recent iron intake. 
  It is the first abnormal laboratory test in iron deficiency. 
Transferrin saturation: 
 It is estimated from serum iron  and total iron binding capacity 
 Second measurement to be affected in iron deficiency anemia 
 Serum iron varies from 60-120 microgram/dl and TIBC is 300-350 
microgram /dl 
 Transferrin saturation <15% indicates iron deficiency. 
Free Erythrocyte Protoporphyrin: 
 It rises with defective iron supply 
 It takes 2-3 weeks to become abnormal after depletion of iron stores 
Serum Transferrin Receptor: 
 Specific and sensitive marker of iron deficiency 
 Its levels are increased in iron deficiency anemia 
 Its facilities are not routinely available 
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Bone Marrow Examination: 
 Invasive test 
 By staining with potassium ferrocyanate, the characteristic blue 
granules of stainable iron in erythroblasts can be seen. 
 It is indicated in  
1. Cases where there is no response to iron therapy after 4 weeks 
2. Diagnosis of kala- azar 
3. Aplastic anemia 
Stool for Ova and cyst: 
Should be done consecutively for 3 days 
Peripheral smear: 
For malarial parasite 
Renal function Test: 
For suspected renal disease 
Serum Proteins- Hypoproteinemia 
Urine Examination 
In Non- pregnant state , iron deficiency can be measured using serum 
ferritin, Transferrin, Serum iron , Transferrin Saturation and Transferrin 
receptors.These tests have their own limitations and are not readily 
available. Interpretation is difficult in situations like Malaria, HIV/AIDS, 
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Vaginosis  and during Pregnancy. Even in women ingesting high amount of 
iron , it is found that Serum ferritin and Bone marrow iron fall during 
pregnancy. This raised the doubt about their significance in pregnancy. 
(Puolakka1980; Romslo1983; Svan berg 1975). 
WHO and CDC Technical Consultation on the Assessment of Iron status at 
population level concluded that serum ferritin and hemoglobin were the 
efficient combination of indicator for monitoring iron status.  
 
CONSEQUENCE OF MATERNAL IRON DEFICIENCY IN 
CHILDREN: 
              “ .   Impaired mental and psychomotor function 
• Impaired sleep patterns and affective relationship 
• Limited attention span 
• Capacity of immune system decreased 
• Increased morbidity from infectious diseases 
• More severe and longer lasting diarrhoea 
• Signs and symptoms of cardiac failure” (Verster A.  WHO 
Guidlelines 1996) 
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EFFECT OF ANAEMIA ON PREGNANCY  
1) Antenatal period: 
a. Early pregnancy loss (abortion). 
b. Increased incidence of urinary tract infection. 
c. Increased incidence of pregnancy induced hypertension  
d. Abruptio placenta 
e. Congestive cardiac failure  
f. Fetal growth restriction  
2) Labour 
a. Labour dysfunction like uterine inertia, precipitate labour 
 b. Prolonged II stage  
3) After delivery (immediate)  
a. Postpartum haemorrhage 
b. Congestive Cardiac failure  
4) After delivery (Late)  
a. Lactation failure  
b. Puerperal sepsis  
c. Deep vein thrombosis  
d. Sub involution of uterus  
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e. Wound infection-for example episiotomy wound & Caeserean section 
wound  
5) Remote  
a. Genital prolapse  
b. General debility  
c. Menstrual abnormalities (41). 
 
Anaemia in pregnancy causes certain problems like abruption, 
pregnancy induced hypertension, urinary tract infection, and 
thrombophlebitis. These are major causes of maternal and perinatal 
morbidity and mortality. 
By correction of anaemia of pregnancy we can drastically reduce 
these problems. Post-partum haemorrhage is a leading cause of maternal 
death in our country because of increased prevalence of anaemia. The cause 
for post-partum haemorrhage in anaemic pregnant women is mainly due to 
decreased myoglobin in uterine musculature consequently leading to 
decreased oxygen perfusion to the uterus. So by correcting anemia, we can 
indirectly prevent postpartum hemorrhage and its attendant morbidity and 
mortality. 
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Prophylaxis: 
Before a women marries and get pregnant she should have adequate 
iron stores. This can be achieved by 
1) Routine screening for anemia for all adolescent girls 
2) Eating iron rich foods 
3) Food fortification with iron 
4) Providing iron supplementation from school days 
5) Annual screening for women with high risk factors. 
 
ORAL IRON: 
 
The preferred route of iron administration is oral. Ferrous salts are 
Inexpensive, have high iron content and better absorbed than ferric salts. The 
most common side effects of oral iron are gastric irritation and Constipation 
which are related to total quantity of elemental iron administered. The 
elemental iron content and not the quantity of iron Compound per dose unit 
is to be taken into consideration. 
 
Sustained release preparations are more expensive and not rational 
because these preparations release part of the iron content lower down in the 
intestine where absorption does not take place. Liquid preparations may 
stain the teeth and they are less satisfactory. Maximal haemopoeitic response 
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is achieved when 200 mg elemental iron given daily in three divided doses.  
Absorption of oral iron is better when it is taken in empty stomach , but side 
effects are more. To overcome the side effects, some prefer to give larger 
amounts after meals, while others prefer to give smaller doses in between 
meals. 
 
 
 
ADVERSE EFFECTS OF ORAL IRON: 
 
The adverse effects are due to elemental iron content. 
 
 Epigastric pain 
 
 Heart burn 
 
 Nausea 
 
 Vomiting 
 
 Staining of teeth 
 
 Metallic taste 
 
 Abdominal colic 
 
 constipation due to astringent action of iron 
 
 Diarrhoea due to reflect irritant action 
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AMOUNT OF IRON IN COMMON IRON PREPARATIONS: 
 
 
PREPARATION Molecular iron 
mg/tablet 
Percentage of 
iron(%) 
Elemental iron 
(mg/tablet) 
Ferrous sulphate 300 20 60 
Ferrous sulphate 
anhydrous 
200 37 74 
Ferrous sulphate, 
dessicated 
200 30 60 
Ferrous Fumerate 200 33 66 
Ferrous 
Gluconate 
300 12 36 
 
PARENTERAL IRON: 
 
INDICATIONS: 
 When oral iron is not tolerated and when the bowel upset is more 
 Failure to absorb oral iron in conditions like malabsorption and 
inflammatory bowel disease 
 Non- compliance to oral iron. 
 In presence of severe deficiency with chronic bleeding 
 Parenteral iron is given along with erythropoietin to meet the demands 
of rapid erythropoiesis. 
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Parenteral iron are of two types 
i)Intramuscular 
ii)Intravenous  
Intramuscular therapy is rarely  used nowdays due to pain and 
discolouration. These are iron sorbitol citric acid complex and Iron dextran. 
There are three types of I V iron preparations 
TYPE I COMPLEXES: 
 Iron Dextran and Iron Dextrin are Type I complexes. 
 They are high molecular compounds. 
 It has got very high stability. 
 Type I Hypersentivity reaction is common. 
 Total dose infusion may be given. 
TYPE II COMPLEXES: 
 These are iron hydroxide sucrose complex. 
 It has got low molecular weight. 
 Biological polymers are not formed in standard doses. 
 Anaphylactic reactions are rare. 
 Can be given up to 200 mg on alternate days. 
 Ferric carboxymaltose can be given up to 1000mg over 15 minutes     
( not available in india) 
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TYPE III COMPLEXES: 
 Iron gluconate, Iron Hydroxide sorbitol complex and Iron Ammonium 
citrate. 
 Low molecular weight. 
 Better side effect profile. 
 Tissue toxicity is more due to more of free iron. 
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IRON SUCROSE 
Iron sucrose is polynuclear iron (III)-hydroxide complex. It is a sterile 
brown coloured fluid   for intravenous use. 
 “Molecular weight about 34,000 - 60,000  daltons” 
 “The osmolarity  is around 1150 mOsmol/L to 1350 mOsmol/L”. 
 “Structural formula: [Na
2
Fe
5
O
8
(OH) • 3(H
2
O)]n • m(C
12
H
22
O
11
)” 
COMPOSITION : 
Each 5 ml contains 100 mg of iron sucrose 
CLINICAL PHARMACOLOGY : 
MECHANISM OF ACTION: 
 
Following intravenous administration, iron sucrose dissociates into 
iron and sucrose by reticuloendothelial system.  
Iron is transferred from the blood into iron pool in the liver and bone 
marrow. 
Iron in a nonionic form is sequestered by ferritin from which iron is 
easily available. 
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Pharmacokinetics: 
 Iron sucrose exhibits first order kinetics 
 Half-life is 6 hours . 
 Total clearance                                         - 1.2 L/h.  
 Steady state  volume of distribution         - 7.9 L  
 Non steady state volume of distribution   -10 L. 
  Clearance of iron from the serum is rapid in patients with iron 
deficiency when treated with iron sucrose. 
 Metabolism and Elimination: 
 Iron sucrose dissociates into iron and sucrose by the reticulo 
endothelial system. The sucrose component is excreted mainly through 
urine.  
CONTRAINDICATIONS: 
• Anemia not due to iron deficiency.  
• Hypersensitivity to drug.  
• When there is evidence of iron overload.  
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SIDE EFFECTS: 
 
Headache, fever, chills, rigor,  pain, asthenia, malaise, abdominal 
pain, flushing metallic taste, nausea, vomiting . 
Delayed reactions like joint pain , myalgia, skin rashes, 
lymphadenopathy and thrombophlebitis at the site of injection may occur. 
  
INTERACTION: 
 
Should not be administered with oral iron preparation because  the 
absorption of oral iron may be reduced. 
 
METHOD AND ROUTE OF ADMINISTRATION 
 
No test dose is required 
 
1. Slow IV injection 
 
100mg (1 amp) to be given undiluted over a period of 2 – 5 min. 
 
2. Slow IV infusion 
 
100mg (1 amp) to be diluted with 100ml of normal saline immediately 
prior to infusion and to be infused over a period of atleast 15min . 
DOSAGE FREQUENCY 
 
100mg/day given on alternate days until the required dose is infused. 
Chandler et al observed that Doses of 200 – 300mg of iron sucrose when 
infused intravenously over 2 hours were well tolerated and safe. Those 
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Patients who received  higher dose of  400 – 500mg intravenously over 2 
hours experienced  side effects like hypotension, nausea, and low back pain 
(56). 
Storage/Stability 
 Vials can be stored at room temperature (59° to 86°F).  
 Protect from freezing. 
 We have to use it immediately after dilution in saline.  
Among all IV preparations iron sucrose is highly efficacious due to 
following reasons 
 It is a nonionic iron complex Which leads on to low toxicity 
 Anaphylactic reactions are rare because biological polymers are not 
formed 
 Iron sucrose is immediately available for erythropoiesis 
 Renal excretion is very low 
 Tissue accumulation is low and so toxicity is less 
 No oversaturation, so adverse reactions are minimal 
Iron sucrose   was used as hematinic therapy for past 50 years. It can be 
used for 
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i) Anemia of chronic kidney disease 
ii) Anemia associated with pregnancy 
iii) In the post surgical period. 
 In November 2000 , FDA approved the clinical use of iron sucrose in 
anemia of chronic hemodialysis patients. Approval for iron sucrose in 
pregnancy and puerperal period was given by FDA in 2005 Oral iron when 
given in appropriate doses correct iron deficiency anemia , but it requires 
high degree of motivation for the people to take it correctly to maintain the 
compliance. Poor compliance is one of the major disadvantage of oral iron.  
Intravenous iron sucrose overcome the problem of compliance and the side 
effects are also minimal. The main advantage is certainity of administration 
and the patient acceptability is also high. The drawback is its cost. But it is 
now made available in all Government institutions free of cost. 
 
 So in order to find an alternative for oral iron in the prophylaxis of 
iron deficiency anemia  which has got many drawbacks, iron sucrose was 
used as prophylaxis in our study.   
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MATERIALS AND METHODS 
This study was conducted in the department of obstetrics and 
gynecology at institute of social obstetrics, kasturba Gandhi hospital 
triplicane, Chennai - 5 from the period of December 2011-december 2012. 
 All Antenatal women attending antenatal OP who fulfill the inclusion / 
exclusion criteria were randomly selected and included in this study. 
 
INCLUSION CRITERIA:  
1. Women booked and immunized in KGH 
2. singleton pregnancy 
3. 20 to 36 weeks of gestation 
4. hemoglobin >10g% 
5. women age 20 to 35yrs 
EXCLUSION CRITERIA: 
1. History of allergic condition or bronchial asthma  
2. History of allergy to iron  
3. Multiple pregnancy 
4. Cirrhosis, viral hepatitis. 
5. History of hematological disease. 
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6. History of bleeding tendency. 
During the Antenatal visit, for all the Women attending the outpatient 
department, the following investigations were done. 
1. Hemoglobin 
2. Packed cell volume 
3. Mean corpuscular volume 
Those who fulfill inclusion criteria were enrolled in the study after 
getting informed consent. A detailed history and complete clinical 
examination was done. 
 
METHODS : 
 Antenatal mothers who were selected were allocated in to one of three 
groups 
1.  Group A ( 100) women  were given only two doses of 200mg of iron 
sucrose between 20-24weeks & 28-32weeks and oral iron was not given to 
this group of patients. 
 
2.  Group B  (100) women   were given  three doses of 200mg of  iron 
sucrose  at 20-24 weeks & 28-32 weeks &34-36 weeks and oral iron was not 
given to this group of patients. 
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3. Group C (100) women  were given 100 tablets of oral ferrous 
sulphate100mg once daily for 3 months between 20 to 36 weeks. 
 
This treatment was supplemented with folic acid , to all the three groups. 
All women were given Tab Albendazole 400 mg in second trimester before 
starting iron therapy. 
 
Before starting therapy blood was taken for all women and the assessment of 
Hb , PCV  ,MCV  was done.  
 
200mg of iron sucrose diluted in 100ml of normal saline(0.9%) was 
given intravenously over a period of 30 minutes as out patient procedure and 
followed up for two hours for any adverse drug events. Emergency drugs 
like steroids, antihistamines were kept ready. Adverse drug events if any 
were noted. 
  
The  parameters that are monitored during intravenous iron therapy are 
1. Vitals – temperature, blood pressure, pulse rate 
2. Adverse effects like nausea, abdominal pain,vomiting chills, etc 
3. Anaphylactic reactions 
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The Response to treatment was monitored by doing the following 
hematological indices  four weeks, eight weeks and at term  . 
1. Hemoglobin 
2. Mean corpuscular volume 
3. Packed cell volume 
The results were statistically analysed using SPSS software. 
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RESULTS AND ANALYSIS: 
 
CHARACTERISTICS OF CASES STUDIED: 
Table 1: AGE DISTRIBUTION: 
 
 
 
Among 300 Women studied, 157 Women (52.3%) belong to age group 
Between 20-24 years, 110 (36.7%) Women belong to age group between 25-
29 years and only 13(11%) women belong to age group between 30-35 
years. 
 20-24 
YEARS 
25-29 
YEARS 
30-35 
YEARS 
TOTAL 
A 54 34 12 100 
B 55 37 8 100 
C 48 39 13 100 
TOTAL    300 
AGE GROUP TOTAL PERCENTAGE 
20-24  YEARS 157 52.3% 
25-29  YEARS 110 36.7% 
30-35  YEARS 33 11% 
 300 100% 
 63 
 
Table 2: SOCIO ECONOMIC STATUS: 
 
 
GROUPS 1 2 3 4 5 TOTAL 
A - - 8 78 14 100 
B - - 10 80 10 100 
C - - 4 81 15 100 
PERCENTAGE   7.3% 79% 13%  
 
 
 
 
Among three hundred Women in our study group, Majority of  Women 
 
 belong to Class IV Socioeconomic status which constitutes 239 (79%)  
 
women, 39 (13%) Women belong to Class V Socioeconomic status and only 
 
 22(7.3%) Women belong to Class III Socioeconomic status . None of them 
 
 belong to Class I and Class II Socioeconomic status. 
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Table: 3: PARITY 
 
 
GROUPS PRIMI MULTI TOTAL 
A 63 37 100 
B 65 35 100 
C 57 43 100 
TOTAL 185 115  
PERCENTAGE 61.7% 38.3%  
 
Among 300 Women in our study, 185 (61.7%) Women were primipara  
which constitutes major portion and 115(38.3%) Women were multipara. 
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Table :4:  HEMOGLOBIN  VALUES IN  GROUP A: 
 
 
HB MEAN SD 
BEFORE 10.644 0.3942 
4WEEKS 11.091 0.2896 
8WEEKS 11.314 0.2425 
AT TERM 11.613 0.1715 
 
CHANGE IN HEMOGLOBIN : 
 
HB MEAN STANDARD 
DEVIATION 
BEFORE 10.644 0.3942 
AT TERM 11.613 0.1715 
CHANGE IN HB 0.969 P <0.005 
 
 
Among 100 Women in group A , the Mean pretreatment Hemoglobin was  
10.644 and the standard deviation was 0.3942 and at term  the mean  
Hemoglobin was 11.613 with Standard deviation of 0.1715 after giving two  
doses of iron sucrose. There is a  Mean rise in  Hemoglobin of about 0.969. 
There is statistically significant rise in Hb with P Value <0.005 
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Table:5 : HEMOGLOBIN  VALUES IN  GROUP B 
 
 
HB MEAN SD 
BEFORE 10.756 0.4222 
4WEEKS 11.208 0.3871 
8WEEKS 11.444 0.3767 
AT TERM 12.357 0.2717 
 
CHANGE IN HEMOGLOBIN : 
HB MEAN STANDARD 
DEVIATION 
BEFORE 10.756 0.4222 
AT TERM 12.357 0.2717 
CHANGE IN HB 1.599 P<0.002 
 
Among 100 Women studied in group B , the mean pretreatment Hemoglobin 
was 10.756, standard deviationwas0.4222 and after giving three  doses of 
iron sucrose , the  Hemoglobin at term was found to be 12.357 with standard 
deviation of 0.2717. The Mean rise in hemoglobin was 1.599.There is a 
statistically significant  rise in Hb from the pretreatment value with P<0.002 
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Table: 6: HEMOGLOBIN VALUES IN GROUP C: 
 
 
HB MEAN SD 
BEFORE 10.705 0.3812 
4WEEKS 11.062 0.3212 
8WEEKS 11.274 0.3111 
AT TERM 11.433 0.2756 
 
CHANGE IN HEMOGLOBIN: 
 HB MEAN STANDARD 
DEVIATION 
BEFORE 10.705 0.3812 
AT TERM 11.433 0.2756 
CHANGE IN HB 0.729 P<0.001 
 
 
Among 100 Women in Group C who were taking oral iron tablets,  the Mean 
pretreatment Hb was 10.705 with standard deviation of  0.3812 and at term 
the mean Hb  was 11.433 with standard  deviation of 0.2756. The mean rise 
in H b was about is 0.729. From the pretreatment value there is a significant 
rise in Hb with  P<0.001.  
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Table: 7: PCV  VALUES IN  GROUP A 
 
 
PCV MEAN SD 
BEFORE 34.62 1.0324 
4WEEKS 35.54 1.005 
8WEEKS 35.28 0.9680 
AT TERM 35.70 0.6540 
 
CHANGE IN PCV 
 
PCV MEAN STANDARD 
DEVIATION 
BEFORE 34.62 1.0324 
AT TERM 35.70 0.6540 
CHANGE IN PCV 1.08 P<0.047 
 
 
The Mean PCV before starting treatment and at term  in Group A was 34.62 
and 35.70 respectively. The Mean change in PCV is 1.08 which is 
statistically significant with P<0.047. 
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Table:8: PCV  VALUES IN  GROUP B 
 
 
PCV MEAN SD 
BEFORE 34.82 0.9974 
4WEEKS 35.24 0.0064 
8WEEKS 35.76 0.7328 
AT TERM 36.20 0.3426 
 
 
CHANGE IN PCV 
 
 
PCV MEAN STANDARD 
DEVIATION 
BEFORE 34.82 0.9974 
AT TERM 36.20 0.3426 
CHANGE IN PCV 1.28 P<0.004 
 
 
 
 
The Mean PCV before starting treatment and at term  in Group B was 34.82 
and 36.20 respectively. The Mean change in PCV was 1.28 which is 
statistically significant with P<0.004. 
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Table :9: PCV  VALUES IN GROUP C 
 
 
PCV MEAN SD 
BEFORE 34.76 1.0284 
4WEEKS 34.24 0.1006 
8WEEKS 35.54 0.7818 
AT TERM 35.72 0.4326 
 
 
CHANGE IN PCV 
 
 
PCV MEAN STANDARD 
DEVIATION 
BEFORE 34.76 1.0284 
AT TERM 35.72 0.4326 
CHANGE IN PCV 0.96 P=0.000 
 
 
 
 
The Mean PCV before starting treatment and at term  in Group C was 34.76 
and 35.72 respectively. The Mean change in PCV is 0.96 which is 
statistically significant with P=0.000. 
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Table: 10: MCV VALUES IN GROUP A 
 
 
MCV MEAN SD 
BEFORE 85.29 1.9808 
4WEEKS 85.73 1.6354 
8WEEKS 86.05 1.4716 
AT TERM 86.44 0.9628 
 
CHANGE IN MCV: 
MCV MEAN STANDARD 
DEVIATION 
BEFORE 85.29 1.9808 
AT TERM 86.44 0.9628 
CHANGE IN MCV 1.15 P=0.03 
 
 
The Mean MCV before starting treatment and at term  in Group A was 85.29 
and 86.44 respectively. The Mean change in MCV was 1.15 which is 
statistically significant with P=0.03. 
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Table: 11: MCV VALUES IN GROUP B 
 
 
MCV MEAN SD 
BEFORE 85.09 1.554 
4WEEKS 85.40 1.426 
8WEEKS 85.51 1.2815 
AT TERM 86.91 0.8162 
 
 
 
CHANGE IN MCV 
 
 
MCV MEAN STANDARD 
DEVIATION 
BEFORE 85.09 1.554 
AT TERM 86.91 0.8162 
CHANGE IN MCV 1.82 P=0.009 
 
 
 
The Mean MCV before starting treatment and at term  in Group B was 85.09 
and 86.91 respectively. The Mean change in MCV was 1.82 which is 
statistically significant with P<0.009. 
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Table: 12: MCV VALUES IN GROUP C 
 
 
MCV MEAN SD 
BEFORE 85.44 1.5543 
4WEEKS 85.40 1.4264 
8WEEKS 85.51 1.2815 
AT TERM 86.91 0.8162 
 
 
CHANGE IN MCV 
 
  
MCV MEAN STANDARD 
DEVIATION 
BEFORE 85.44 1.5543 
AT TERM 86.91 0.8162 
CHANGE IN MCV 1.47 P=0.07 
 
 
 
 
The Mean MCV before starting treatment and at term  in Group C was 85.44 
 
 and 86.91 respectively. The Mean change in MCV is 1.47 with P<0.07. 
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Table :13: CHANGES IN PCV IN ALL GROUPS: 
 
 
 GROUP  A GROUP B GROUP C 
 MEAN SD MEAN SD MEAN SD 
BEFORE 34.62 1.0324 34.82 0.9974 34.76 1.0284 
4 
WEEKS 
35.54 1.0005 35.24 1.0064 34.24 0.1006 
8 
WEEKS 
35.28 0.9680 35.76 0.7328 35.54 0.7818 
AT 
TERM 
35.70 0.6540 36.20 0.3426 35.72 0.4326 
P<0.047 P<0.004 P<0.000  
                                                                                          
 
The mean change in PCV in Group A from the pretreatment value to PCV at  
term is  1.08, the mean change in PCV in Group B is 1.38 and the mean 
change in PCV in Group C is 0.96. The mean PCV within  groups before 
starting therapy and at term is  statistically significant P<0.047,P<0.004, 
P<0.000 respectively. when  compared between groups,there is  no 
statistically significant rise in PCV.  
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Table :14: CHANGES IN MCV: 
 
 GROUP  A GROUP B GROUP C 
 MEAN  SD MEAN SD MEAN SD 
BEFORE 85.29 1.9808 85.09 1.5543 85.33 1.4461 
4 
WEEKS 
85.73 1.6354 85.40 1.4264 85.40 1.4264 
8 
WEEKS 
86.05 1.4716 85.51 1.2815 85.40 1.4128 
AT 
TERM 
86.448 0.9628 86.91 0.8162 86.10 0.7221 
P=0.03 P=0.009 P=0.07 
 
The Mean rise in MCV from pretreatment value to MCV at term is 1.15 in  
Group A, 1.82 in Group B and 0.76 in Group C.There is a statistically  
significant  rise in MCV with  intravenous groups (p=0.03, p=0.009 for 
Group A  and Group B respectively) when compared between pretreatment 
and at term than oral group (p=0.07) .when analysis was done between 
groups there is no statistically significant rise in MCV.  
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Table: 15: CHANGES IN HB: 
 
 GROUP  A GROUP B GROUP C 
 MEAN  SD MEAN SD MEAN SD 
BEFORE 10.644 0.3942 10.756 0.4222 10.705 0.3812 
4 
WEEKS 
11.091 0.2896 11.208 0.3871 11.062 0.3212 
8 
WEEKS 
11.314 0.2425 11.444 0.3767 11.274 0.3111 
AT 
TERM 
11.613 0.1715 12.353 0.2717 11.433 0.2756 
P=0.005 P=0.0002 P=0.001 
 
The mean pretreatment HB in all the three Groups is same.  The mean 
degree of raise in HB in Group A is 0.969 , the mean HB rise in Group B is 
1.599 and the mean HB rise in Group c is 0.729. ONE WAY ANOVA test 
was performed with in groups, which showed a statistically significant rise 
in HB from the pretreatment value to HB at term in all groups. Then student 
T test was performed to know the statistical significance between groups. 
There is statistically significant (P< 0.000) rise in HB in Group B , who were 
given  three doses of  intravenous iron sucrose when compared to Group C 
who were given  oral  iron supplementation and Group A who were  
given two doses of iron sucrose. 
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Table: 16: ADVERSE DRUG EVENTS: 
 
ADE INTRAVENOUS 
IRON SUCROSE 
ORAL IRON 
Local pain 2(1%) - 
Burning sensation at 
infusion 
- - 
Giddiness 2(1%) - 
Rashes 1(0.5%) - 
Gastritis - 15(15%) 
Constipation - 8(8%) 
Diarrhoea - 2(2%) 
Chest discomfort 1(0.5%) - 
Palpitation 1(0.5%) - 
Anaphylaxis - - 
 
Out of 200 Women who received intravenous iron sucrose, 3.5% of them 
had minor adverse drug events like local pain, giddiness, rashes , palpitation 
and chest discomfort which was treated symptomatically. There were no  
major Anaphylactic reactions noted during this study. On the contrary 25% 
of Women had  minor gastrointestinal side effects in the oral group which is 
the common cause of non- compliance. 
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DISCUSSION 
  
 In our study, antenatal women attending the Antenatal Outpatient 
Department who fulfill the inclusion, exclusion criteria stated in the 
methodology were selected and assigned to one of the three groups. Women 
belonging to Group A and B were given two and three doses of iron sucrose  
respectively, each dose containing 200 mg of iron sucrose. Group C women 
were given 100 tablets of ferrous sulphate. Hemoglobin, Packed cell volume, 
Mean Corpuscular Volume were assessed 4 weeks,8 weeks and at term. Any 
adverse reaction during the therapy noted. The results were analysed.  
 
 Among 300 Women studied, 157 Women (52.3%) belong to age 
group Between 20-24 years, 110 (36.7%) Women belong to age group 
between 25-29 years and only 13(11%) women belong to age group between 
30-35 years.  
 
 
 Among three hundred Women in our study group , 239 Women which 
constitutes 79% belong to Class IV Socioeconomic status, 39 (13%) Women 
belong to Class V Socioeconomic status and only 22(7.3%) Women belong 
to Class III Socioeconomic status. None of them belong to Class I and Class 
II Socioeconomic status. 
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 Among 300 Women in our study, 185 (61.7%) Women were 
primipara. 115(38.3%) Women were multipara,this suggest that anemia is 
common in multipara due to previous pregnancy events ,short interdelivery 
interval. 
 
COMPARISION OF OUTCOME PARAMETERS: 
 
I) COMPARISION OF HEMOGLOBIN: 
 
  Among 100 Women in group A , the Mean pretreatment Hemoglobin 
was 10.644 and the standard deviation was 0.3942 and at term  the mean 
Hemoglobin was 11.613 with Standard deviation of 0.1715 after giving two 
doses of iron sucrose. There is a  Mean rise in Hemoglobin of about 0.969 
which is statistically significant with p=0.005. 
 Among 100 Women studied in group B , the mean pretreatment  
 
Hemoglobin was 10.756 and after giving three doses of iron sucrose , the 
 
 Hemoglobin at term was found to be 12.357. The Mean rise in hemoglobin  
 
was 1.599  which is statistically significant with p=0.0002 
 
                Among 100 Women in Group C who were taking oral iron tablets, 
the Mean pretreatment Hb was 10.705 with standard deviation of  0.381 and 
at term the mean Hb  was 11.433 with standard deviation of 0.2756. The 
mean rise in H b was about is 0.729 which is statistically significant with 
p=0.001. 
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 Gabriela Bencaivo et al conducted a study to assess and compare the 
efficacy of two and three doses of iron sucrose with daily supplementation 
of oral ferrous sulphate in the prophylaxis of iron deficiency anemia in 
pregnant women.There was a non significant trend to a higher frequency of 
responders in the intravenous iron group (75%vs 80%). 
 
 When the hemoglobin >11g/dl is considered as responders. Hb before 
delivery in the intravenous group was 12+/-0.9 and 12.4+/-1.1 in oral group 
with p value of 0.110. HCT and MCV in the intravenous group was 87.4+/-  
5.7 and 35.2+/-2.1 respectively and in the oral group it was 86.6+/-5.7,  
35.6+/-3.1 with p value of 0.259, 0.222. 
 
 The efficacy of iron prophylaxis was demonstrated by an significant 
increase in Hb and HCT in the intravenous and oral iron group (p<0.001 and 
P<0.01).Serum ferritin , which is the best indicator of body iron stores 
showed a absolute rise in women with three doses of iron prophylaxis. 
Eighty percent of women with three doses of intravenous iron and 71% with 
two dosess of intravenous iron exhibited Hb >11g/dl after iron 
supplementation. Our study is comparable to this study. 
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ii) COMPARISION OF PCV AND MCV: 
 
  The mean change in PCV in Group A from the pretreatment value to 
PCV  at term is  1.08, the mean change in PCV in Group B is 1.38 and the 
mean change in PCV in Group C is 0.96.There is a statistically significant 
rise in PCVwith in groups from the pretreatment to at term. Although the 
mean PCV between groups is not statistically significant, there is slight rise 
in PCV in Group B compared to other two groups.  
 The Mean rise in MCV from pretreatment value to MCV at term is 
1.15 in  Group A, 1.82 in Group B and 0.76 in  Group C. There is 
statistically significant rise in MCV with in groups when compared to 
pretreatment to at term. There is no statistically significant rise in MCV in 
the intravenous group compared to oral group.  
 Our study could be compared to Gabrielo Bencaivo et al European 
journal of obstetrics and gynecology and reproductive biology 144 (2009) 
135- 139. In this study iron prophylaxis was given as intravenous and oral 
and the efficacy compared. 
 According to this study HCT before delivery in intravenous group  
was 35.2+/-2.1 and 35.6+/-3.1 in the oral group. There is no significant 
change in HCT in both intravenous and oral group. MCV was 87.4+/-5.7 in 
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the intravenous group and 86.6+/-5.7 in the oral group. Our study is 
comparable to this study.   
 
 The mean pretreatment HB in all the three Groups is same.  The mean  
degree of raise in HB in Group A is 0.969 , the mean HB rise in Group B is 
1.599 and the mean HB rise in Group c is 0.729. ONE WAY ANNOVA test 
was performed with in groups, which showed a statistically significant rise 
in HB  from the pretreatment value in each groups. Then student T test was 
performed to know the statistical significance between groups. There is 
statistically significant( P= 0.000) rise in HB in Group B , who were given 
three doses of  intravenous iron sucrose when compared to Group C who  
were given  oral  iron supplementation and Group A who were given two  
doses of iron sucrose. 
 Out of 200 Women who received intravenous iron sucrose, 3.5% of 
them had minor adverse drug events like local pain, giddiness, rashes , 
palpitation and chest discomfort which was treated symptomatically. There 
were no major Anaphylactic reactions noted during this study. On the 
contrary 25% of  Women had  minor gastrointestinal side effects in the oral 
group which is common cause for non – compliance. 
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In our study we gave iron sucrose at 4 weeks interval  as prophylaxis 
and found highly significant rise in hemoglobin concentration as also 
reported by Françoise B et al who gave iron at weekly interval. While Al-
Memon et al reported no significant difference in the effectiveness of iron 
sucrose over oral iron for elevating Hb concentration during pregnancy. 
               Contrary to the conclusion of Reveiz et al regarding parenteral iron 
therapy about possible serious adverse effects, in our study compliance 
with iv iron therapy was good.In daily practice,  physicians often face poor 
compliance with oral therapy because of digestive side effects which can 
lead to worsening of anemia. In these cases parenteral forms of 
administration are indicated as well as in those patients in whom oral 
treatment is ineffective.        
Intravenous iron therapy was found safe, convenient and more 
effective than intramuscular iron therapy in treatment of iron deficiency 
anemia during pregnancy by Wali et al.The effects of parenteral iron therapy 
on the baby should be investigated in further studies. 
Our study showed that three dose of intravenous iron sucrose therapy 
in the prophylaxis of iron deficiency anemia in pregnant women showed 
significantly raised hemoglobin levels when compared to two doses and oral 
iron. 
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 Iron sucrose therapy as prophylaxis can reduce the maternal mortality 
and  morbidity to a significant level. Iron sucrose therapy can be a first line 
of prophylaxis in view of its easy accessibility , safety and good efficacy 
compared to oral iron. 
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SUMMARY 
 
 In our study 300 Antenatal Women attending the Antenatal out Patient 
department who fulfill the inclusion criteria were randomly selected and 
divided into one of the three groups. Initially Hemoglobin, Packed cell 
volume, Mean corpuscular volume was done in all the Women. Group A and 
B Women were given two and three doses of intravenous iron sucrose 
respectively. Group C Women were given oral ferrous sulphate. The 
following parameters were analysed after 4 weeks, 8 weeks and at term. 
1. Hemoglobin in g/dl. 
2. Packed cell volume. 
3.  Mean corpuscular volume. 
 Statistical package for social science (SPSS) was used for statistical 
compilation and analysis. For Statistical analysis of difference between 
groups, analyses of covariance or t-test were applied when appropriate. 
Statistical significance was accepted as P<0.05. 
 The results of the study are tabulated, analysed and summarized as follows. 
1. Majority of women 157 (52.3%) belong to the age group between20-
24 years. 
2. In this study Majority of women 239(79%) belong to Class IV 
Socioeconomic status. 
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3. Most of the Women 185 (61.7%) were primipara in our study. 
4. The Mean PCV within groups before starting therapy and at term is 
statistically significant P<0.001. When compared between groups, 
there is no statistical signifance in PCV between intravenous and oral 
group. 
5. The Mean MCV within groups before starting therapy and at term is 
statistically significant P<0.001. When compared between groups 
there is no statistically significance in MCV between intravenous and 
oral group. 
6. Mean rise in HB at term is 0.969 in group A,1.599 in Group B, 0.729 
in Group C. There is statistically significant rise in HB fro 
pretreatment value to HB at term in all the three groups. Group B is 
statistically significant P<0.000 when compared to Group A and 
Group C. 
7. Only 3.5% of  Women had minor drug events in intravenous iron 
sucrose group. No major Anaphylactic reactions noted during our 
study. But 25% of Women on Oral iron had side effects of 
gastrointestinal symptoms.                                                                                 
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CONCLUSION 
1. From our present study , Intravenous iron sucrose is highly efficacious 
in  improving  hemoglobin when compared to oral iron in the 
prophylaxis of iron deficiency anemia. There is no statistical 
difference between intravenous group and oral group in terms of 
packed cell volume, Mean corpuscular volume. 
2. Three dose of iron sucrose improves hemoglobin significantly   with 
no serious side effects, compared to two doses of iron sucrose and oral 
ferrous sulphate in the prophylaxis of iron deficiency anemia in 
pregnancy. 
3. Intravenous iron sucrose was well tolerated and safe and there were 
no major adverse reactions. 
To conclude three doses of intravenous iron sucrose is safe, 
convenient, more effective in the prophylaxis of gestational anemia 
compared to oral iron.  
 
Intravenous Iron sucrose could be a better alternative to oral ferrous 
sulphate In the prophylaxis of iron deficiency anemia in pregnancy so as to 
reduce the maternal mortality and morbidity.  
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                                        PROFORMA 
 
                STUDY OF IRON PROPHYLAXIS IN PREGNANCY – 
                INTRAVENOUS VERSUS ORAL ROUTE 
 
Name:                                                                     Age : 
OPNo:                                                                                                  
Address: 
 
Occupation:                                                              Phone no: 
Income:                                                                   Group: 
Socioeconomic Class: 
Obstetric score: 
Gravida: Para:   Live:      Abortions: 
 
Presenting complaints: 
 
H/o Easy fatiguability / giddiness/Hook worm infestation 
 
H/o Bleeding per vaginum/ Hematemesis / malena 
  
H/o Anorexia / indigestion/ Breathlessness/ Swelling of legs 
 
H/o Multiple pregnancy /Puffiness of face /Iron intolerance 
 
Past H/o: 
 
H/o Blood loss in between pregnancy 
 
H/o DM, HT, Asthma, epilepsy, TB 
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Menstrual H/o: 
 
Age at menarche:         Cycles: Regular/ Irregular              flow: 
 
Obstetric History: 
 
H/o Antepartum Hemorrhage / Postpartum Hemorrhage/ Blood Transfusion 
 
General Examination: 
 
Features of anemia: Yes/ No 
 Pallor /Glossitis / Facial Puffiness/ Koilonychia  
 
VITALS: 
 
Temp:                      PR:                               BP: 
CVS:                                                             RS:                                                                                                
Investigations: 
To rule out iron deficiency anaemia: 
1. Hb: 
2. Urine:  Albumin 
Sugar, deposits 
3. Peripheral smear 
4. PCV: 
5. MCV: 
POST THERAPY ASSESSMENT: 
 Pre 
Treatme
nt 
4 Weeks  8 Weeks At Term 
HB     
PCV     
MCV     
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Parameters monitored during therapy: 
Adverse effects Yes/ No 
 
1. Anaphylactic reaction 
(Shivering, Hypotension) 
 
2. Nausea / Vomiting 
 
3. Thrombophlebitis 
 
4. Abdominal Pain/gastritis 
 
5. Diarrhea/ constipation 
 
6. Chills / Rigors 
 
7. Joint pain 
 
8. Giddiness 
 
9. Palpitation 
 
10. Chest discomfort 
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ABBREVATIONS 
 
 
WHO    -World Health Organisation 
 
CDC              - Center for Disease Control 
 
ICMR                 - Indian Council of Medical Research 
 
HB                       - Haemoglobin 
 
MCV                   - Mean Corpuscular Volume 
 
PCV                    - Packed Cell Volume 
 
RBC                   - Red Blood Corpuscles 
 
I.V                     - Intravenous  
 
TIBC                 - Total Iron Binding Capacity 
 
NNACP            - National Nutritional Anemia Control Programme 
 
NFHS               - National Family Health Survey 
IDA                  - Iron Deficiency Anemia 
DLHS              - District Level Household Survey 
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1 Saraswathy     20 6000 G3P2L2 IV 10.2 34 86 10.2 34 87.2 10.8 35 88 11.8 34.1 86.4 0 
2 Rekha          20 5883 G2P1L1 IV 10.6 35 87 10.8 36 87.1 11.2 35 88 11.6 35 86.2 0 
3 Amudha         28 6201 Primi IV 10.4 34 86 10.6 36 86.5 10.9 36 85 11.5 32.4 85.5 0 
4 Nalini         28 6190 G2P1L1 IV 10.2 33 80 10.6 34 82.7 10.6 35 82 11.6 33.4 82.5 0 
5 Indra          24 6232 Primi IV 10.9 34 88 10.7 36 88.2 11 35 88 11.5 35 86.4 0 
6 Rajalakshmi    27 6367 Primi V 10.8 35 89 10.7 36 87.2 11.2 36 86 11.4 33.6 85.4 0 
7 Ezhilarasi     21 1720 Primi IV 10.5 35 84 10.8 38 87.2 11.2 36 86 11.8 34 84.1 0 
8 Vishalakshi    22 6905 Primi IV 10.4 34 85 10.8 35 85.6 11 35 86 11.6 34.2 84 0 
9 Tamilselvi     31 6845 Primi IV 10.8 34 86 11.2 35 86.1 11.3 34 85 11.5 34.2 84.5 0 
10 Thenmozhi      28 6814 Primi IV 10.4 34 85 10.8 35 85.9 11.2 33 86 11.7 34.6 85 0 
11 Deepika        23 7151 Primi IV 10.2 34 86 10.6 35 85 11.2 36 84 11.5 34.2 86.2 0 
12 Maimoon        33 7173 G2A1 IV 10 33 81 10.8 35 82.3 11.1 35 83 11.4 33.8 83.2 0 
13 Dhavamani      27 7196 G2P1L1 V 10.2 33 88 10.8 33 88.2 11 34 88 11.6 34 86.7 0 
14 Lakshmi        25 7406 G2P1L1 III 10.2 33 86 10.8 34 87 11.1 34 87 11.6 34.2 84.6 P 
15 Nithyapriya    22 7809 Primi IV 10.7 34 84 10.8 36 84.2 11 35 86 11.6 34.2 84 0 
16 Levinrani      24 8028 Primi III 10.7 35 86 10.8 35 86.4 11.2 36 88 11.6 34.8 86.8 0 
17 Parveen        25 8090 G3P1L1A1 IV 10.5 34 84 10.8 36 84 11 34 86 11.5 33.9 84.2 0 
18 Janani         22 8503 Primi IV 10.4 34 87 10.9 36 87.2 11 37 88 11.5 36.2 86 0 
19 Nancy          20 9092 G3P1L1A1 IV 10.2 33 84 10.9 36 85 11 34 87 11.4 34.2 84.5 0 
20 Lavanya        30 10031 Primi IV 10.2 33 86 10.9 35 86.4 11.2 35 88 11.5 34.8 86 0 
21 Uma            20 10025 G2A1 IV 10.6 35 84 10.9 37 86.5 11.2 36 85 11.4 33.7 85.2 0 
22 Suganya        21 10544 G3PIL1A1 IV 10.6 35 86 10.9 36 85.9 11.1 34 88 11.3 32.8 85.4 0 
23 Abirami        24 9437 G2A1 IV 10.4 34 82 10.9 35 84 11.2 36 84 11.5 34.7 84.1 0 
24 Pavithra       24 10798 G2P1L1 III 10.6 35 86 10.9 36 87 11.2 35 86 11.5 34.9 86.2 0 
25 Jamuna         24 11078 G2P1L1 V 11 36 85 11.1 36 85.6 11.4 37 85 11.8 33 85.1 0 
26 Sharmila       27 11241 G1A1 IV 10.4 34 83 10.9 34 84.2 11.2 33 84 11.8 34 82 Pa 
27 Radhika        28 11466 Primi IV 10.7 35 86 10.9 35 87.3 11.2 35 87 11.7 35.6 86.4 0 
28 Maheshwari     30 11640 Primi IV 10.5 34 85 10.9 36 84 11.1 34 86 11.6 35.8 85.2 0 
29 Nagammal       34 11852 G2P1L1 IV 10.2 33 87 10.9 35 82 11.1 33 88 11.5 35.2 84.2 0 
30 Manimegalai    23 11992 G2P1L1 IV 10.6 34 84 10.9 35 84.6 11.2 35 84 11.4 35.1 84.2 0 
31 Renuka         25 12161 Primi IV 10.4 34 86 10.9 37 86.9 11 37 88 11.4 34.1 86.2 0 
32 Kamatchi       35 12369 Primi V 10.2 33 84 11 34 85 11.4 36 86 11.6 34.2 84.1 0 
33 Reetamary      25 12444 Primi IV 10.2 33 86 11 34 86.2 11.4 34 86 11.7 34.2 85.2 0 
34 Revathy        27 12674 Primi IV 10.1 33 87 11 35 86 11.3 35 86 11.6 35.4 86.3 0 
35 Bhavani        20 12885 G2P1L1 III 10.2 33 82 11 35 84.3 11.3 35 83 11.6 35.3 85.5 0 
36 Revathy        25 13245 Primi IV 10.2 34 82 11 36 82 11.4 36 87 11.5 33.2 85.2 0 
37 Prema          28 13421 Primi IV 11.4 36 88 11.6 36 87 11.8 36 87 11.9 34.2 84 0 
38 Gayathri       27 13562 G4P1L1A2 IV 10.4 34 84 11 35 84 11.3 36 87 11.6 35.8 84 0 
39 Devi           21 13736 Primi IV 10.2 33 85 11.1 34 84 11.2 36 86 11.5 33 85.2 0 
40 Devi           22 14063 G2P1L1 III 10.4 34 84 11.1 36 84 11.5 36 85 11.8 33.1 84.2 0 
41 Bhuvaneshwari  23 5724 G3P1L1A1 IV 10.4 35 84 11.1 36 85.6 11.4 33 85 11.6 33.4 84.5 0 
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42 Priya          20 14522 Primi IV 10.6 34 82 11 35 84.2 11.4 35 83 11.5 34 85.2 0 
43 Nirmala        23 14755 Primi IV 10.6 35 89 11.1 36 88 11.4 36 86 11.6 35.4 86.2 0 
44 Subhashini     21 15124 G2A1 IV 10.8 35 85 11.2 36 85 11.2 34 86 11.5 35.2 86.4 0 
45 Shobana        20 15273 Primi IV 10.4 34 84 11.2 35 83.9 11.4 35 83 11.4 36.3 83.2 0 
46 Selvi          21 15590 Primi V 10.4 334 85 11 35 85.6 11.4 34 86 11.6 35.6 84.6 0 
47 Preethi        22 14658 Primi V 10.5 36 84 11.2 36 85.7 11.4 36 86 11.8 35.8 86 0 
48 Gowri          23 14662 G2P1L1 IV 10.4 34 86 11.2 35 85 11.4 35 88 11.6 34.7 85.2 0 
49 Kalpana        25 15825 G2A1 IV 10.6 34 82 11.1 34 83.4 11.3 35 85 11.6 34 88.3 0 
50 Lavanya        27 16288 Primi IV 10.3 34 86 11 35 86.5 11.3 36 87 11.5 33.2 84.2 0 
51 Jhansirani     28 16327 G2P1L1 V 10.9 35 82 11.2 35 83.2 11.3 36 84 11.6 34 83.4 0 
52 Shanthi        33 16463 G3P1L1A1 IV 10.4 34 84 11.2 36 87 11.4 36 84 11.8 34.5 85.4 0 
53 Menaga         21 16843 G2P1L1 IV 11.6 36 83 11.8 37 83 11.9 34 84 12 35.2 85 0 
54 Sakunthala     22 16895 G2P1L1 V 10.6 35 85 11.1 36 85.4 11.3 36 86 11.5 35.4 84.6 0 
55 Vanitha        23 17434 G2A1 IV 10.9 36 81 11.3 36 84.3 11.4 35 87 11.6 35.2 85 0 
56 Thulasi        20 17669 Primi V 10.8 35 84 11.2 36 85.7 11.4 36 86 11.5 34.2 84.9 0 
57 Amala          22 17916 Primi IV 10.9 36 84 11.3 36 88 11.5 36 87 11.6 35.3 84.5 0 
58 Durga          24 18058 Primi IV 10.8 35 87 11 37 84 11 35 86 11.5 35.4 87 0 
59 Selvi          24 18110 G2P1L1 III 10.7 35 87 11.3 35 86.4 11.3 36 85 11.6 34.8 86.3 0 
60 Backiyalakshmi 25 11176 Primi IV 10.3 34 85 11 34 84.6 11.2 35 86 11.5 35.4 85.4 0 
61 Shalini        27 18464 G2P1L1 IV 10.8 35 85 11.2 36 85.6 11.4 34 86 11.6 36.5 84.5 0 
62 Clara          33 18417 Primi V 11.4 36 87 11.4 36 87.2 11.6 33 87 11.8 35.1 87.1 0 
63 Rajalakshmi    23 18680 Primi IV 10.8 34 88 11.4 34 88 11.4 34 89 11.9 34.8 86.1 0 
64 Priya          32 18707 Primi IV 10.5 34 86 11.1 36 85.2 11.4 35 87 11.5 34.6 85.4 0 
65 Selvi          28 18838 G2P1L1 IV 10.8 36 82 11.2 36 83.4 11.4 36 84 11.6 35.3 84.2 0 
66 Priyadharshini 20 18821 Primi IV 11 36 87 11.3 36 86.2 11.2 37 86 11.7 34.4 87 0 
67 Jothilakshmi   20 18952 Primi IV 10.9 36 85 11.3 36 86.5 11.4 36 88 11.4 35 84.3 0 
68 Sindhuja       20 19091 Primi IV 10.8 35 84 11.2 36 85.6 11.4 36 88 11.5 35.1 84.1 0 
69 Sumalatha      20 19055 Primi IV 10.5 34 89 11 36 87 11.4 36 84 11.6 35 86 0 
70 Fathima        21 19402 Primi IV 10.2 33 82 11 35 82.1 11.4 35 84 11.7 33.5 82.3 0 
71 Mala           25 19484 Primi V 10.8 36 84 11.3 36 83.8 11.5 36 84 11.8 34.6 85.6 0 
72 Ramya          25 19715 Primi IV 10.8 35 82 11.2 35 82.6 11.5 36 85 11.6 35 82 0 
73 Aruldeepa      26 19987 Primi IV 10.9 36 85 11.4 37 85 11.5 37 85 11.7 35.1 83.1 0 
74 Renganayagi    28 19990 G2P1L1 V 10.4 34 83 11.4 36 11.6 10.6 35 87 11.8 35 83.4 0 
75 Meena          21 20011 G2P1L1 IV 10.7 35 85 11.2 36 85.3 11.4 37 85 11.7 34.8 86.2 0 
76 Chandra        28 20296 G2P1L1 IV 10.7 35 85 11.2 36 85.2 11.5 35 87 11.9 35.4 85 0 
77 Ramya          32 20294 G2A1 IV 10.5 34 87 11 35 87.7 11.2 35 88 11.4 33.5 86.4 0 
78 Revathy        25 20347 Primi IV 10.5 34 85 11 36 85.9 11.2 35 86 11.4 34.5 86.4 Gi 
79 Aishwarya      21 20377 G2P1L1 IV 10.5 35 85 11.5 38 86.2 11.6 36 86 11.7 33.9 84.1 0 
80 Suguna         28 20576 Primi IV 10.8 35 84 11.3 36 85.9 11.4 35 85 11.8 34.9 85.3 0 
81 Manjula        20 20571 G3PIL1A1 IV 10.6 34 85 10.9 35 86 11.2 35 86 11.9 34 86 0 
82 Geetha         20 20595 Primi III 10.6 35 85 11.2 37 85.9 11.4 35 86 11.5 35.2 84.2 0 
83 Jebina         22 20830 G2P1L1 IV 10.7 35 86 11.1 36 86.7 11.2 36 87 11.4 35.2 86.4 0 
84 Sasikala       24 19707 Primi IV 10.5 34 89 11 35 88 11.2 35 88 11.6 34.8 86.4 0 
85 Dhakshayini    26 20952 Primi IV 11 36 87 11.2 37 87.6 11.5 36 88 11.5 35.4 85.4 0 
86 Ruby           27 21085 G2P1L1 IV 11.2 36 88 11.5 37 88.6 11.7 36 88 11.4 35.2 86.2 0 
87 Malathy        20 21287 G3P2L2 IV 10.6 35 89 11.4 35 88 11.8 36 87 11.8 34.8 85.4 0 
88 Malathy        21 21267 Primi IV 11.4 36 86 11.6 37 87.6 11.8 37 88 11.8 33.9 85.4 0 
89 Sathya         24 21351 Primi III 11.8 34 86 11.8 38 87.2 12 36 86 11.8 35.4 85.2 0 
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90 Shenbagavalli  31 12409 Primi IV 10.5 34 86 10.9 37 86.4 11.4 34 87 11.9 34.6 86.2 0 
91 Riswana        27 21599 G2P1L1 IV 11.3 36 88 11.6 36 87.2 11.6 37 87 11.8 34.2 86.7 0 
92 Jeyalakshmi    20 19531 G3P1L1A1 IV 10.9 35 84 11.2 37 84.6 11.4 37 86 11.5 35 84.2 0 
93 Indhumathy     23 15425 G2P1L1 V 10.5 35 83 10.9 37 83 11.2 36 83 11.4 34.2 83.2 0 
94 Renu           26 21858 Primi V 10.6 34 89 11 35 87.9 11.2 35 88 11.4 35.1 86.6 0 
95 Saridha        30 21908 G2P1L1 IV 10.8 36 89 11.3 34 87.5 11.5 36 86 11.6 35 82.3 0 
96 Rajimunisha    20 22100 Primi IV 10.4 35 89 10.9 37 88 11.6 36 87 11.7 34 84.2 0 
97 Mariammal      26 22066 G3P1L1A1 IV 11.2 36 89 11.3 37 88 11.6 36 88 11.6 35.4 86.4 0 
98 Vijayakumari   22 17370 Primi IV 10.6 35 87 11 37 87 11.3 36 87 11.5 34.2 84 0 
99 Shameemnisha   20 22267 Primi IV 12.2 35 87 12.1 36 86.8 11.5 36 86 12.4 35.2 85.6 0 
100 Priya          26 22243 Primi IV 12 36 86 11.9 35 86.2 11.9 34 86 11.9 35.4 85.2 0 
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1 Razia          20 5944 IV Primi 10 33 81 10 35 84.5 10.9 35 85 12.1 34.2 82.4 0 
2 Radha          24 5894 IV G2P1L1 10.5 34 85 11 35 85.6 10.9 35 86 12.3 34.2 86.9 0 
3 Mubeena        22 6115 IV G3P2L2 10.6 35 85 11 34 83 11.1 34 84 12.1 35.9 85.6 0 
4 Kavya          30 6384 IV G3A2 10.4 34 85 11 35 85.8 10.8 35 86 12.2 34.5 84.9 0 
5 Manju          30 6380 IV Primi 10.6 33 85 11 34 86.7 10.9 36 85 12.4 34.9 85 0 
6 Ammu           27 6537 III G2A1 10.8 36 84 11 35 85.3 11.2 35 85 12.1 36.8 84.8 0 
7 Ambikadevi     27 6673 IV G2A1 10.5 35 84 11 36 85.2 11.2 36 86 12.5 35.9 85.6 0 
8 Kanniga        26 6703 V Primi 10.5 34 85 11 36 84.6 11.2 36 84 12.6 35.7 86.4 0 
9 Nandhini       21 6704 IV G2A1 10.2 35 89 11 36 86.6 11.9 34 87 12.4 35.6 88.7 0 
10 Saranya        20 6625 IV G2P1L1 10.2 33 80 11 34 82.2 10.9 34 82 12.4 34.6 81.5 0 
11 Selvarani      21 6954 IV Primi 10.9 35 87 11 35 88 11.9 36 88 12.8 35.8 87 0 
12 Shakila        27 6969 IV G2A1 10.9 34 83 11 34 85.6 10.6 35 86 12.9 33.9 84.2 0 
13 Bama           25 6992 IV Primi 10.6 36 84 11 36 85.3 10.9 36 85 12.3 36 85.4 0 
14 Sangeetha      21 7321 IV G2 10.2 35 84 11 34 85.2 11.1 35 85 12.5 35.6 84.2 Gi 
15 Renuga         25 3177 IV G2P1L1 10.1 35 85 11 35 84.2 11 35 85 12.8 35.4 85.2 0 
16 Karpagavalli   20 7630 V G3P1L1A1 10.4 34 84 11 34 85.3 10.9 35 86 12.4 34.8 85.6 0 
17 Nandhini       20 8050 IV G3P1L1A1 10.6 34 82 11 34 84.5 11.1 35 83 12.8 35.2 83.2 0 
18 Subha          21 8444 IV Primi 10.6 36 82 11 37 83.2 10.9 37 83 12.9 36.1 83 0 
19 Nithya         21 8973 IV Primi 10.2 33 85 11 34 84 11.2 35 85 12.8 34.2 84.5 0 
20 Revathy        22 10263 IV G2P1L1 10.2 34 83 11 35 85.2 11.4 35 85 12.6 35.2 84 0 
21 Mahalakshmi    25 10355 IV G2P1L1 10.4 34 84 11 35 85 11.6 35 85 12.8 36 84.2 0 
22 Vahidha        22 10632 III G3P2L2 10.8 35 84 11 34 87 11.2 34 87 12.7 35.6 85.6 0 
23 Kanimozhi      22 5962 IV Primi 10.8 33 85 11 34 85.1 11.2 36 85 12.5 35.8 85.4 0 
24 Sudha          27 10999 IV Primi 10.5 34 87 11 34 85.6 11 35 86 12.7 33.7 87 0 
25 Geetha         28 10922 V Primi 10.2 33 82 11 34 84.4 11.1 35 86 12.6 35.6 83.2 0 
26 Banumathy      26 11347 IV G2A1 10.4 36 85 11 36 85.9 11.2 36 86 12.5 36.4 85.6 0 
27 Nagadevi       24 11535 IV G2P1L1 10.4 34 83 11 34 80 11.2 36 82 12.3 34.8 82.5 0 
28 Belsi          24 11731 IV G2P1L1 10.4 34 87 11 35 85.1 11.1 35 87 12.6 34.3 86.5 0 
29 Lakshmipriya   25 11900 IV Primi 10.8 34 84 11 35 84 10.9 36 84 12.4 34.6 84.2 0 
30 Padmavathy     25 12212 III G2A1 10.8 35 84 11 36 85.6 11.5 36 86 12.1 35.4 84.8 0 
31 Saradha        26 12266 V Primi 10.7 35 87 11 36 86.6 11.1 36 87 12.5 35.8 86.5 P 
32 Mariam         25 12452 IV G2A1 10.5 35 86 11 36 87 11 36 87 12.4 35.4 86.5 0 
33 Nalini         27 12572 IV G2P1L1 10.5 35 85 11 36 85.1 11.2 36 85 12.4 34.7 85 0 
34 Vannamayil     24 12713 IV G2A1 10.6 35 87 11 35 87.6 11.2 36 88 12.1 35.8 87 0 
35 Komala         22 12921 IV Primi 10.2 35 84 11 35 83.9 11.2 35 84 11.9 35.5 84.6 0 
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36 Jerinabegum    24 13329 IV Primi 10.2 36 86 11 36 86.2 11.1 36 86 12.2 36.2 86.4 0 
37 Sabiya         21 13461 IV G2P1L1 10.4 34 86 11 37 87.2 11.6 37 87 11.8 34.7 86.7 0 
38 Divya          22 13657 IV G2P1L1 10.7 35 85 11 36 85.2 11.2 36 86 12.1 35.4 85.4 0 
39 Kavitha        25 13743 IV Primi 10.6 34 86 11 36 84.2 11.4 35 84 11.7 35.2 87 0 
40 Padmavathy     23 14145 IV G3P1L1A1 10.8 37 84 11 36 86.2 11.5 36 86 11.9 37 84.3 0 
41 Devi           25 14306 IV G2P1L1 10.4 35 85 11 36 85.2 11.2 36 86 12.5 34.9 84.8 R 
42 Sasi           24 14337 IV Primi 10.9 35 84 11 35 84.8 11.6 36 86 12.3 35.6 84.5 0 
43 Shantha        24 14597 IV Primi 10.8 35 84 11 36 85.2 11.9 37 86 12.5 36.4 85.4 0 
44 ThelathBee     25 14777 IV Primi 10.8 35 87 11 35 87 11.6 35 87 12.4 35.7 87.2 0 
45 Sujatha        26 15210 IV Primi 10.5 35 89 11 34 85.4 11.6 35 86 12.6 35.4 85 0 
46 Prabhavathy    27 15352 IV Primi 10.6 34 86 11 35 86 11.4 36 86 12.5 35.1 86.2 0 
47 Sathya         21 15757 IV Primi 10.8 34 84 11 34 85.5 11.4 35 83 12.3 34.7 84.2 0 
48 Sathya         21 15925 IV Primi 10.4 34 85 11 34 85.1 11.5 35 86 12.4 34.6 85.6 0 
49 Divya          21 15972 IV Primi 10.2 34 86 11 35 86.8 11.8 36 86 12.6 35.4 86.2 0 
50 Jothi          22 16269 IV G2P1L1 10.9 34 84 11 34 85.3 11.4 35 86 12.2 34.1 84.2 0 
51 Sindhu         22 16632 IV G2P1L1 10.5 34 86 11 36 84.3 11.1 36 84 12.4 35.6 86.5 0 
52 Gomathy        23 16671 V G2A1 11 36 86 11 37 86 11.6 36 86 12.1 35.7 86.4 0 
53 Dhanalakshmi   30 16998 V Primi 11.4 36 87 11 36 87 11 36 86 12.2 35.9 87.1 0 
54 Supriya        24 17332 IV G3P2L2 10.5 34 87 11 34 85.4 11.6 37 85 12.3 35.4 86.8 0 
55 Janani         32 17537 III Primi 10.5 36 85 11 35 85.1 11.6 35 85 12.4 35.8 85.4 0 
56 Sharmila       20 17621 IV Primi 11.2 36 85 11 36 87.4 12 37 87 12.4 35.9 85.4 0 
57 Shanthi        24 18038 IV G2P1L1 11 34 85 11 34 85.3 11.2 36 85 12.5 34.9 85.4 0 
58 Mercy          27 18209 IV G2P1L1 10.6 35 86 11 35 87.2 11.2 35 87 12.5 35.7 86.2 0 
59 Tamilselvi     22 18468 IV Primi 11 34 85 11 33 85.2 11.5 34 86 12.3 35 85.4 0 
60 Sangeetha      25 11991 IV Primi 10.8 34 87 11 37 87.6 11.4 36 86 12.4 34.8 86.9 0 
61 Stella         23 16826 IV Primi 11 36 87 11 36 86.2 11.6 36 86 12.3 36.4 86.5 0 
62 Sofia          29 18531 IV G2P1L1 10.6 37 85 11 36 83.8 11.5 35 84 12.5 36.1 84.2 0 
63 Samantha       26 18527 IV Primi 10.9 36 86 11 37 85.3 11.5 37 86 12.2 35 87.1 0 
64 Mythili        31 18853 IV G2P1L1 10.6 35 86 11 36 85.2 11.5 37 85 12.4 35.4 86.4 0 
65 Saritha        23 18811 IV Primi 10.8 35 87 11 36 86.9 11.8 36 85 12.3 35.4 87.2 0 
66 Sarathy        20 18592 III Primi 11.2 33 84 11 34 88.2 11.8 36 88 12.5 34.2 85 0 
67 Vasanthi       21 18586 IV Primi 10.9 35 86 11 36 86.3 11.5 37 86 12.1 36.4 86.4 0 
68 Amutha         22 18978 IV Primi 11 36 87 11 36 86.2 11.6 36 86 11.9 35.4 86.5 0 
69 Ramya          23 19128 IV Primi 10.8 34 89 11 35 84.6 11.6 36 85 11.8 35.2 87 0 
70 Jansirani      23 19203 IV Primi 10.9 34 84 11 35 85.2 11.7 35 86 12.2 35.8 85.4 0 
71 Nirmala        24 19217 III G3P1L1A1 11.2 37 89 11 36 87.2 11.8 36 87 12.4 36.8 88 0 
72 Renuga         25 19616 IV Primi 11 37 88 11 37 87 11.6 37 87 12.5 36.9 87.2 0 
73 Vijayalakshmi  29 19641 IV G2P1L1 10.9 36 82 11 36 83.1 11.6 36 83 12.4 35.8 82.3 0 
74 Sathya         25 19654 V G2A1 11 36 87 11 36 87.2 11.6 37 87 12.1 36.5 87.6 0 
75 Priya          31 19886 IV G3P2L2 10.6 35 85 12 36 86 10.9 36 86 11.9 35.8 85.6 0 
76 Suguna         27 20111 IV G2A1 10.5 34 84 12 38 85.4 11.6 37 85 11.9 34.6 86.4 0 
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77 Saridha        28 20129 III Primi 10.9 36 85 12 36 85.6 11.8 36 87 12.2 36.5 84.6 0 
78 Jabbuthin      21 20185 IV Primi 10.9 35 82 12 34 83.2 11.5 36 83 12.4 35.2 83.4 0 
79 Gomathy        21 20442 IV Primi 11 36 85 12 36 87.1 11.6 36 87 12.6 35.4 85.4 0 
80 Kosaladevi     27 20608 IV Primi 10.9 34 86 12 34 88 11.8 36 88 12.4 35.4 86.2 CD 
81 Sivasakthi     25 20628 IV G3P1L1A1 10.3 34 85 12 37 83 11.4 37 84 12.8 34 85.3 0 
82 Bhuvaneshwari  26 20603 V G2P1L1 11.2 36 86 12 35 83 11.4 35 83 12.6 36.2 86 0 
83 Renuga         28 20754 IV G2A1 11.2 35 86 12 36 86.9 11.4 36 86 12.8 35.8 86.8 0 
84 Sabana         20 20971 IV Primi 10.7 35 86 12 36 86.5 11.4 36 87 12.4 35.8 87.2 0 
85 Leelavathy     20 21074 IV Primi 10.9 36 85 12 36 83.2 11.8 37 84 12.5 36.2 83 0 
86 Mangai         23 21152 IV Primi 10.8 34 86 12 35 86.3 11.8 36 87 12.6 35.2 86.2 0 
87 Razia          24 21218 IV G2P1L1 11.8 32 87 12 33 83.5 11.6 35 84 12.7 35.7 86.9 0 
88 Ganga          28 21230 IV G2P1L1 10.9 37 84 12 37 85 11.9 37 85 12.4 37 84.9 0 
89 Mohana         20 21493 III G2P1L1 10.5 35 84 12 35 84.2 12.1 37 85 12.5 33 85.2 0 
90 Kamatchi       21 21519 IV Primi 11.4 36 84 12 37 84 11.8 37 84 12.4 36.4 84.8 0 
91 Anitha         22 21689 IV Primi 10.9 35 84 12 36 85.1 11.4 36 85 12.1 35.4 85.1 0 
92 Selvi          22 20657 IV Primi 11.2 36 87 12 37 86.2 11.9 36 86 11.9 35.8 87.2 0 
93 Velvizhi       24 21875 IV G4P1P1A2 10.8 36 84 12 35 84.2 11.7 35 86 11.8 35.8 84.2 0 
94 Kamatchi       30 21823 IV Primi 11.8 34 85 12 34 88.2 12 37 88 11.8 36.4 86.2 0 
95 Ruckmani       24 21985 III Primi 10.8 34 84 12 34 84.2 11.6 35 84 12 35 85.1 0 
96 Meena          25 22233 IV Primi 10.5 34 84 12 35 83.4 11.9 36 83 12.2 35.4 83 0 
97 Gayathri       24 22698 V G2A1 12 37 85 12 36 85.2 12.2 37 86 12.1 37.2 85.1 0 
98 Aswini         29 22791 V G2P1L1 11.6 36 84 12 37 84.6 12.2 37 85 12.1 36.2 85.2 0 
99 Devi           25 22972 IV G3P1L1A1 11.6 35 86 12 36 85.6 12 37 86 12.2 34 85.6 0 
100 Muniyammal     33 22623 III Primi 12.6 35 87 13 35 86.7 12.9 36 87 12.5 35.4 86.2 0 
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1 Devika         24 5879 IV G2P1L1 10.1 35 83 10 35 85.3 10.5 35 84 11 35.4 83.8 0 
2 Vahitha        24 5980 IV Primi 10.6 34 86 11 35 85.6 10.8 36 86 11.2 34.5 85.9 0 
3 Mahalakshmi    29 6081 IV G2P1L1 10.3 34 83 11 37 83 11.4 37 84 11.4 34.6 84.6 0 
4 Yasmin         22 6065 IV Primi 10.8 36 86 11 37 83.2 11 36 86 10.8 35.9 85.9 G 
5 Padmavathy     20 6303 IV Primi 10.1 34 82 11 35 84.5 10.8 35 83 10.8 33.2 83 0 
6 Elavarasi      23 6357 IV Primi 10.2 33 83 11 34 82.2 10.9 35 83 11.2 33 82.1 0 
7 Saraswathy     25 6374 IV Primi 10.2 35 86 11 35 85.8 10.9 35 86 11.1 34.2 84.6 0 
8 Sivagami       31 6460 V Primi 10.1 34 83 11 34 84.4 10.7 35 84 11 33.4 84.2 C 
9 Yamini         20 6519 III G2P1L1 10.6 35 84 11 34 83 10.9 35 85 11.2 35.9 85.4 0 
10 Jothilakshmi   23 1792 IV G2A1 10.2 33 83 11 35 83.9 11 34 83 11.2 34.2 83.5 0 
11 Vidhya         26 6816 IV G2P1L1 10.5 34 84 11 34 84.5 11.2 34 85 11.1 34.2 83.9 0 
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12 Rubeena        20 7015 IV G2P1L1 10.5 34 84 11 34 85.6 10.9 36 84 11.2 34.1 83.6 C 
13 Sheela         25 7060 IV Primi 10.9 35 86 11 36 85.2 11.1 36 86 11.3 35.6 85.9 0 
14 Esther         23 7157 IV Primi 10.5 34 86 11 34 85.6 11.4 35 86 11.6 34.6 85.6 G 
15 Sharmila       20 7235 IV G2P1L1 10.8 33 86 11 34 86.7 11.1 35 86 11.4 33.1 85.4 0 
16 Seethalakshmi  26 7345 IV G2P1L1 10.2 33 85 11 36 86.6 11.1 36 84 11.2 34.2 85.1 0 
17 Padmavathy     23 7544 IV Primi 10 34 87 11 36 84.6 11 35 87 11.1 35.2 86.7 G 
18 Sumithra       28 7586 IV Primi 10.8 35 86 11 36 85.2 10.9 36 86 11.4 35.4 86.4 0 
19 Megala         20 7587 V G2P1L1 10.4 34 84 11 35 84 11.2 36 85 11.5 34.2 85 0 
20 Vidhya         21 7686 III G2P1L1 10.8 37 83 11 36 86.2 10.9 35 84 11.1 36.4 83.2 0 
21 Vannapetchi    23 7980 IV G2P1L1 10.4 34 85 11 37 87.2 11.2 36 86 11.5 34.2 85.2 D 
22 Deepa          24 7931 IV Primi 10.5 34 84 11 36 87.1 11 36 85 11.2 33.9 84.6 0 
23 Lakshmi        25 8048 V Primi 10.6 34 86 11 35 86 11 36 865 11.1 34.1 86.5 0 
24 Suryakala      26 8112 IV G2A1 10.4 34 86 11 36 85.2 11.4 36 86 11.8 33.4 85.4 D 
25 Sangeetha      27 8265 IV G2P1L1 10.2 33 84 11 34 84 10.8 35 85 10.9 35.4 83.6 0 
26 Karpagam       19 8437 IV G2P1L1 10.8 35 85 11 35 88 11.2 35 86 11.5 34.8 85.6 0 
27 Kavitha        20 8633 IV G2A1 10.2 34 83 11 35 83.4 11.2 36 84 11.2 34.8 83.2 0 
28 Elakiya        24 8791 IV Primi 10.4 34 85 11 34 85.3 11.2 36 87 11.4 35.2 85.4 G 
29 Sivagami       29 8937 V Primi 10.2 34 85 11 36 83.8 11 36 85 11.1 34.5 84.7 0 
30 Fathima        30 9148 IV Primi 10.1 33 87 11 35 84.2 11 36 86 11.1 33.6 86.3 0 
31 Eswari         26 9326 III G2P1L1 10.6 35 84 11 35 87 11.4 35 85 11.5 34.2 84.2 0 
32 Janani         22 9546 IV G2P1L1 10.2 35 84 11 34 85.2 10.9 34 86 11 34.2 84.1 0 
33 Priya          23 9772 V G2P1L1 10.4 34 87 11 36 85.9 11 36 86 11.2 35.2 87.2 C 
34 Dhanalakshmi   25 9865 IV Primi 10.4 34 83 11 34 80 11 35 84 11.1 34.1 84.2 0 
35 Kalaivani      28 10317 IV G2P1L1 10.5 33 86 11 36 85.1 11.4 36 86 11.4 33.9 86 G 
36 Kala           30 10392 IV Primi 10.6 34 86 11 34 85.1 11.2 34 86 11.5 34.1 86.4 0 
37 Koteeshwari    21 10486 IV Primi 10.8 35 83 11 34 87 11.1 35 85 11.3 34.8 84.1 G 
38 Mumtaz         28 9382 IV G2P1L1 10.9 36 86 11 36 85.6 11.2 37 86 11.5 35.8 86.2 0 
39 Meera          33 10700 IV G2P1L1 10.7 35 85 11 36 86.6 11.4 36 85 11.4 35.3 85.1 0 
40 Manjula        30 10855 IV Primi 10.8 36 87 11 37 85.3 11.4 37 87 11.6 35.4 86.4 0 
41 Vijayalakshmi  34 10905 IV  Primi 10.5 36 87 11 35 87.6 11.6 35 86 11.8 35.2 86.4 0 
42 Kavitha        21 11144 IV G2A1 10.5 36 84 11 35 85.1 10.9 35 83 11.1 35.8 84.7 0 
43 Ayesha         21 11258 IV Primi 10.9 35 86 11 34 83.2 11.2 35 85 11.5 34.9 86.2 C 
44 Rekha          25 11377 V Primi 10.8 35 85 11 34 85.5 11.3 35 85 11.5 35 85.4 0 
45 Rajeshwari     21 11580 IV G2P1L1 10.5 34 85 11 36 84.2 11.3 36 86 11.6 34.2 85.4 0 
46 Parvathy       22 11708 IV G2P1L1 11.5 36 87 11 36 87 11.2 36 87 11.4 35.1 86.2 G 
47 Gomathy        29 11758 IV Primi 11.2 36 86 11 37 86.2 11.4 36 87 11.5 36.2 85 0 
48 Aishwarya      24 11916 III Primi 10.5 35 85 11 38 85.4 11.2 37 86 11.6 35.6 85.7 cons 
49 Gowsalya       22 12025 IV Primi 10.2 33 84 11 36 86.2 11.5 36 85 11.6 34.2 84.2 0 
50 Parveen        20 12020 IV G3P1L1A1 10.5 35 88 11 36 84.3 11.4 35 88 11.5 36.5 87.4 0 
51 Praveena       23 11005 IV Primi 10.7 36 83 11 36 83.1 11.2 36 83 11.1 35.9 83.2 0 
52 Kodumpadi      27 12345 IV Primi 10.6 34 86 11 34 84.2 11.2 35 87 11.4 34.2 86.3 0 
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53 Malliga        27 12365 V Primi 10.6 33 85 11 35 86.8 11.2 36 85 11.1 34.1 84.7 0 
54 Ramani         26 12410 IV G2P1L1 11.1 36 88 11 37 86 11.2 37 87 11.5 35 87.6 gas 
55 Shanthi        33 12536 IV G2A1 10.9 36 85 11 35 84.8 11.3 35 85 11.5 35.4 84.6 0 
56 Meenakshi      20 12574 IV G3P1L1A1 11.2 37 87 11 37 87 11.4 36 86 11.5 36.4 87.2 0 
57 Lakshmi        21 12691 IV G2P1L1 10.8 34 86 11 36 85.2 11.4 36 85 11.5 34.2 85.7 0 
58 Parameshwari   25 12761 IV Primi 10.5 35 86 11 36 87 11.2 36 86 11.5 34.8 86.4 0 
59 Sharmila       27 12877 IV Primi 10.5 36 85 11 36 86 11.3 36 86 11.6 35.2 85.6 0 
60 Devika         30 13031 IV Primi 10.5 35 85 11 35 84.2 11.3 36 85 11.3 34.9 85.1 0 
61 Meenakshi      23 13090 IV G2A1 10.6 36 84 11 34 85.1 11.3 34 84 11.3 33.4 84.9 0 
62 Selvi          25 13185 IV G2P1L1 10.5 36 85 11 34 85.4 11.4 35 86 11.5 34.2 84.2 G 
63 Saritha        26 13388 IV G2P1L1 10.6 34 87 11 35 85.1 11.3 35 86 11.4 34.5 85.4 0 
64 Yuvarani       30 13385 IV Primi 10.9 36 88 11 35 84.6 11.4 35 88 11.6 36.1 87.9 0 
65 Bharathi       21 13538 IV G3A2 10.7 34 88 11 34 88 11.4 35 86 11.6 34.8 87.4 0 
66 Sathyabama     30 13734 IV Primi 10.7 34 85 11 34 85.4 11.3 35 86 11.5 34.2 84.9 0 
67 Sathya         20 13877 V Primi 10.6 35 85 11 36 85.2 11.5 37 86 11.6 35.4 85.4 0 
68 Radhika        29 13992 IV G2P1L1 10.4 34 84 11 35 85 11.4 35 84 11.2 36.2 84.5 0 
69 Amudha         26 14074 IV G3P2L2 10.8 35 83 11 35 83 11.4 36 85 11.5 35.4 83.9 C 
70 Jothi          21 14280 IV Primi 10.5 33 86 11 36 86.3 11.4 36 85 11.6 33.4 85.4 0 
71 Geetha         30 14340 IV G2P1L1 10.8 36 87 11 37 87.6 11.6 36 86 11.6 35.4 87.2 0 
72 Radha          20 14460 IV G2P1L1 11 36 87 11 36 86.2 11.4 37 87 11.2 36.4 87.2 D 
73 Selvi          23 14498 IV G2A1 11.6 33 87 11 33 83.5 11.2 34 87 11.2 34.8 86.4 0 
74 Sumathy        24 14750 IV Primi 11.6 34 87 12 34 88.2 11.8 34 87 12 33.9 86.4 0 
75 Deepa          25 14934 V Primi 10.5 37 87 11 37 85 11.4 37 87 11.5 35.9 86.4 0 
76 Nagooramma     22 15223 V G2P1L1 10.8 36 86 11 36 85.3 11.4 36 86 11.6 35.4 85.4 0 
77 Varalakshmi    24 15300 IV Primi 11.2 33 84 11 34 85.3 11.8 35 85 11.7 33.8 84.2 G 
78 gnanavalli     25 15443 IV G2P1L1 10.8 35 84 11 35 85.2 11.4 35 86 11.5 35.3 84.3 0 
79 Sangeetha      26 15676 V Primi 11 36 88 11 35 86.3 11.5 35 88 11.6 35 86.5 0 
80 Gayathri       26 15764 IV Primi 11.2 37 88 11 36 87.2 11.5 37 88 11.6 36.4 87.2 0 
81 Usha           27 15824 V G2P1L1 10.6 35 85 11 35 87.2 11 35 87 11.3 35.2 84.2 0 
82 Radha          29 15961 IV G2P1L1 11 37 87 11 33 85.2 11.4 34 86 11.8 36.5 86.5 0 
83 Vijayalakshmi  31 16026 IV G2P1L1 11.6 36 85 11 36 87.4 11.4 36 85 11.9 35.7 85.4 C 
84 Kanagalakshmi  19 16053 IV G2A1 11 36 85 11 36 87.2 11.7 35 86 11.7 35.2 85.4 0 
85 Bagavathy      29 16152 IV Primi 11.2 36 85 11 34 88.2 11.6 34 85 11.8 35.2 85.4 0 
86 Vinothini      23 16306 IV Primi 10.9 36 85 11 36 83.2 11 36 85 11.3 35.5 84.6 G 
87 Pushpa         20 16375 IV G3P1L1A1 11.1 36 88 12 36 85.6 11.2 36 88 11.4 35.4 87 0 
88 Nandeeshwari   28 16423 IV G2P1L1 10.9 35 87 11 36 86.9 11.4 36 86 11.6 35.2 85 0 
89 Indrani        31 16575 IV Primi 10.8 36 84 11 36 86.5 11.5 36 85 11.6 35 84.4 G 
90 Laavanya       27 16597 IV Primi 10.9 35 88 11 36 85.1 11.5 36 87 11.6 35.4 86.5 0 
91 Backiyalakshmi 20 16751 V Primi 11.2 35 84 12 36 86.9 11.6 36 85 11.8 35.2 84.3 0 
92 Senthamarai    21 16928 IV G2P1L1 10.9 35 84 12 35 85.2 11.6 35 86 11.4 35.6 84.6 0 
93 Anitha         24 17218 IV G2P1L1 10.9 34 83 11 34 85.3 11.4 34 85 11.4 34.8 83.4 0 
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94 Rekha          28 17277 IV Primi 10.5 35 85 11 36 85.2 11.4 36 86 11.6 36.2 85.2 G 
95 Varalakshmi    26 17537 IV Primi 10.9 34 86 11 36 85.6 11.5 37 84 11.7 33.9 87 0 
96 Gunasundari    22 17675 IV G2P1L1 11.4 36 87 12 37 84 11.5 37 87 11.8 36.4 86 0 
97 Anandhi        26 17728 V G2A1 10.5 36 86 11 35 84.2 11.6 36 86 11.7 35.9 84.9 G 
98 Parimala       29 17768 V Primi 11.2 35 87 12 36 86.2 11.8 36 85 11.8 35.9 86 0 
99 Vetriselvi     29 18013 IV G2P1L1 11.6 37 86 12 37 86.2 11.9 35 85 12.2 36 85.5 0 
100 Sabina         22 16976 IV G2P1L1 11.8 35 87 12 35 86.7 12.2 37 88 12.4 35.4 86.5 G 
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KEY TO MASTER CHART 
 
 
SE STATUS       -  socioeconomic status 
 
CD                      - Chest discomfort 
 
G                         -   Gastritis 
 
C                         - Constipation 
 
D                         - Diarrhoea 
 
Pa                        - Palpitation 
 
R                         - Rashes 
 
Gi                       - Giddiness 
 
P                         - Local Pain 
 
 
